WO1994022864A1 - Acyclic nucleoside analogs and oligonucleotide sequences containing them - Google Patents

Acyclic nucleoside analogs and oligonucleotide sequences containing them Download PDF

Info

Publication number
WO1994022864A1
WO1994022864A1 PCT/US1994/002995 US9402995W WO9422864A1 WO 1994022864 A1 WO1994022864 A1 WO 1994022864A1 US 9402995 W US9402995 W US 9402995W WO 9422864 A1 WO9422864 A1 WO 9422864A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
formula
alkyl
methyl
compound
Prior art date
Application number
PCT/US1994/002995
Other languages
French (fr)
Inventor
Philip D. Cook
Daniel J. Delecki
Charles Guinosso
Original Assignee
Sterling Winthrop Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc. filed Critical Sterling Winthrop Inc.
Priority to AU64493/94A priority Critical patent/AU6449394A/en
Priority to DE69404289T priority patent/DE69404289T2/en
Priority to EP94912266A priority patent/EP0691968B1/en
Priority to JP6522133A priority patent/JPH08508492A/en
Publication of WO1994022864A1 publication Critical patent/WO1994022864A1/en
Priority to GR970402699T priority patent/GR3025053T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Definitions

  • the present invention relates to novel 1, ⁇ - alkylenediol nucleoside analogs, to oligonucleotide
  • oligonucleotide analogs containing this unit were hybridized with complementary natural oligonucleotides. The results were described by the authors as "disappointing for those hoping to use flexible oligonucleotide analogs as antisense compound". The replacement of even a single nucleoside in a nonamer resulted in a melting temperature depression of 12 to 15o in the duplex.
  • R is hydrogen or a phosphate residue
  • B is cytosine, thymine, guanine or adenine.
  • An antisense compound is a compound that binds to or hybridizes with a nucleotide sequence in a nucleic acid, RNA or DNA, to inhibit the function or synthesis of said nucleic acid. Because of their ability to hybridize with both RNA and DNA, antisense compounds can interfere with gene expression at the level of transcription, RNA
  • Antisense molecules can be designed and synthesized to prevent the transcription of specific genes to mRNA by hybridizing with genomic DNA and directly or indirectly inhibiting the action of RNA polymerase.
  • a theoretical advantage of targeting DNA is that only small amounts of antisense compounds may be needed to achieve a therapeutic effect.
  • antisense compounds can be designed and synthesized to hybridize with RNA to inhibit post-transcriptional modification (RNA processing) or protein synthesis (translation) mechanisms or affect mRNA stability.
  • RNA processing messenger RNA
  • tRNA transfer RNA
  • rRNA ribosomal RNA
  • hnRNA heterogenous nuclear RNA
  • processing and translation mechanisms include splicing of pre-mRNA to remove introns, capping of the 5' terminus of mRNA, transport to the cytoplasm, hybridization arrest and
  • Synthetic antisense molecules are susceptible to rapid degradation by nucleases that exist in target cells.
  • the oligonucleotide sequences of antisense DNA or RNA are destroyed by exonucleases acting at either the 5' or 3' terminus of the nucleic acid.
  • endonucleases can cleave the DNA or RNA at internal phosphodiester linkages between individual nucleotides. As a result of such cleavage, the effective half-life of
  • Another problem is the extremely high cost of producing antisense DNA or RNA using available semiautomatic DNA synthesizers.
  • a further problem relates to the delivery of antisense agents to desired targets within the body and cell.
  • Antisense agents targeted to genomic DNA must gain access to the nucleus (i.e. the agents must permeate the plasma and nuclear membrane).
  • the need for increased membrane perme- ability increased hydrophobicity
  • aqueous solubility increased hydrophilicity in body fluid compartments such as the plasma and cell cytosol.
  • a still further problem relates to the stability of antisense agents whether free within the body or
  • sequences such as antisense DNA are susceptible to steric reconfiguration around chiral phosphorous centers.
  • Gene targeting via antisense agents is the pre- dieted next step in human therapeutics [Armstrong, Business Week March 5, 1990 p.88].
  • the successful application of antisense technology to the treatment of disease requires finding solutions to the problems set forth above.
  • One approach to preparing antisense compounds that are stable, nuclease resistant, inexpensive to produce and which can be delivered to and hybridize with nucleic acid targets throughout the body is to synthesize oligonucleotide sequences with modifications in the normal phosphate-sugar backbone structure and the point of attachment to the nucleotide base. This invention is directed to such an approach.
  • R 1 is hydrogen or a blocking group that is
  • R 2 is hydrogen, nitro, lower alkyl amino, diloweralkyl amino or methyl
  • R 3 is hydrogen or -P(R 4 )OR 5
  • R 4 is chloro, imidazolyl, 4- nitroimidazolyl, tetrazolyl, triazolyl or dilower-alkylamino preferably diisopropylamino
  • R 5 is methyl, 2,2,2- trichloroethyl or 2-cyanoethyl, preferably 2-cyanoethyl
  • X is oxygen, sulfur or -NR 6 -, preferably oxygen
  • R 6 is
  • n 0 to 2 and Q is a heterocyclic residue chosen from the group consisting of
  • R 7 is lower-alkyl or loweralkyloxy methylene and R 8 is hydrogen, benzoyl, anisoyl or lower-alkylcarbonyl.
  • the point of attachment of the heterocycle O is at the 8- position carbon rather than the 9-position nitrogen as in naturally-occurring nucleosides.
  • the invention relates to an oligonucleotide sequence of from about 6 to about 200 bases, preferably from about 12 to about 24 bases, most preferably about 15 bases, in which one or more nucleosides are replaced by a residue of formula V
  • the compounds of formula I are useful as intermediates in the synthesis of the oligonucleotide sequences in which one or more residues are replaced.
  • oligonucleotide sequences are useful as antisense agents, for the inhibition of gene expression, in nucleic acid sequencing, diagnostic assays and for the inhibition of nuclease degradation.
  • lower-alkyl means a hydrocarbon radical consisting of from about one to about four carbons in straight chains, branched or cyclic structures.
  • Nucleoside and nucleotide have their standard meanings in the art: i.e. a nucleoside is a nucleoside base attached to a ribose or a 2-deoxyribose through the 9- position of the purine or the 1-position of the pyrimidine; a nucleotide is a 3' or 5' ribose-O-phosphate ester of a nucleoside.
  • Nucleoside bases comprise uracil, thymine, cytosine, guanine, adenine and their variously modified and derivatized congeners as known in the art.
  • modified and derivatized bases include 5-fluorouracil, 5- bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, dihydrouracil, inosine, N6- isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2, 2-dimethylguanine, 2- methyladenine, 2-ethylguanine, 3-methylcytosine, 5-methyl- cytosine, N6-methyladenine, 7-methylguanine, 5-methyl- aminomethyluracil, 5-methoxyuracil, pseudouracil, queuosine, 2-thiocytosine, 5-methyl-2-thiour
  • compositions for inhibiting gene expression comprising the modified oligonucleotides described above and a pharmaceutically acceptable carrier.
  • the invention relates to a method of inhibiting gene expression and to a method of inhibiting nuclease, particularly exonuclease, degradation of oligonucleotide sequences, which comprises providing a modified oligonucleotide described above.
  • the invention pertains to processes for preparing compounds of formula II
  • R 9 and R 10 are hydrogen, in which case the compounds of formula II are obtained directly, or protecting groups for a hydroxyl function, in which case the compounds of formula II are obtained by removal of the protecting groups by means known in the art.
  • Preferred leaving groups, Y are bromine, chlorine, iodine, toluenesulfonate, and methanesulfonate; most preferred is bromine.
  • Preferred protecting groups are t-butyl, benzyl, phenyl or substituted phenyl or isopropylidene; most preferred is isopropylidene.
  • the invention relates to a process for the synthesis of modified oligonucleotides in which a nucleoside is replaced by a residue of formula V
  • DMT stands for the dimethoxytrityl residue and O a is the subset of O wherein R 8 is other than hydrogen (R 8a ) .
  • O a is
  • oligomers wherein R 8 is hydrogen are then obtained from the corresponding R 8a oligomers by deprotection using methods well-known in the art.
  • 8- bromoguanine is acylated with an appropriate acid chloride or anhydride, preferably isobutyric anhydride, and alkylated with an appropriate lower-alkyl halide or sulfonate, preferably methyl iodide to produce a 2-acyl-9-alkyl-8- bromoguanine of formula Vila.
  • adenine is alkylated with a lower- alkyl halide or sulfonate, preferably methyl iodide, brominated with molecular bromine at pH 4.0 in aqueous acetic acid-sodium acetate buffer and acylated with an acid chloride or anhydride, preferably benzoyi chloride to produce a 4, 4-diacyl-9-alkyl-8-bromoadenine Vllb.
  • a lower- alkyl halide or sulfonate preferably methyl iodide, brominated with molecular bromine at pH 4.0 in aqueous acetic acid-sodium acetate buffer and acylated with an acid chloride or anhydride, preferably benzoyi chloride to produce a 4, 4-diacyl-9-alkyl-8-bromoadenine Vllb.
  • n is 0 to 2, preferably 0 or 1 and it is preferred that the sodium salt of the alcohol be preformed by the addition of one equivalent of sodium hydride.
  • the 8- bromopurine is then added to the alcoholate in the inert solvent.
  • X is sulfur or -NR 6 - it is not necessary to protect the 1, ⁇ -dihydroxyl functionality i.e.
  • R 9 and R 10 may be hydrogen, and it is not necessary to preform the sulfur or nitrogen anions.
  • R 9 and R 10 are other than hydrogen, it is necessary to convert them to hydrogen after condensation with the bromopurine by appropriate deprotection.
  • X is oxygen and R 9 and R 10 together form a propylidene residue (Ilia)
  • deprotection is
  • the compounds of formula Ila are prepared for incorporation into oligonucleotide sequences by protection of one hydroxyl with 4, 4' dimethoxytrityl chloride according to procedures well-known in the art [see Schaller, Lerch and Khorana, J. Am. Chem. Soc. 85 3821-3827 (1963)] followed by reaction of the other hydroxyl with about 3 equivalents of 2-cyanoethyl N,N-diisopropylchlorophosphoramidite in THF also according to procedures known in the art [see Sinha et al. Tet. Lett.
  • the compounds of formula VI that are preferred for further elaboration into sequences are the compounds in which R 4 is diisopropylamino and R 5 is ⁇ -cyanoethyl, but other "monomers" (VI) in which R 4 is chlorine, imidazole, 4-nitroimidazole, tetrazole, triazole, or other dilower-alkylamines and R 5 is methyl or 2,2,2-trichloroethyl may also be made by procedures known in the art [see Matteucci and Caruthers Tet . Lett. 22., 1859- 1862 (1981) and Schaller et al. op. cit.]
  • the monomer unit VI and its precursor X are chiral compounds.
  • synthesis as shown may be incorporated into oligomers, giving rise to diastersomeric sets of oligomers, which may themselves be separated if desired, or the enantiomers may be separated at the monomer stage.
  • Common techniques that may be used if resolution is desired include chromatography on chiral media or the promotion of diasterosomeric esters of X with single enantiomers of chiral acids, separation of the diasteromers and hydrolysis to provide single
  • the compounds of formula VI are incorporated into oligonucleotide sequences by the substitution of a compound of formula VI for its corresponding dimethoxytrityl
  • nucleoside phosphoramidite in standard procedures for the synthesis of oligonucleotides.
  • solid phase syntheses such as those described by Matteucci and Caruthers [J. Am. Chem. Soc. 103, 3185-3191 (1981)] and Gait [Olignnucieotide Synthesis: A Practical Approach, ed. by M.J. Gait p. 35-81 IRL Press, Washington, D.C. 1984.]
  • the initial step in solid phase synthesis is attachment of a nucleoside to a solid support, preferably a controlled pore glass (CPG) support.
  • CPG controlled pore glass
  • the nucleoside is preferably attached to the CPG via a succinate linkage at the 3'-hydroxy position of the nucleoside.
  • Other means of attaching nucleosides to solid supports are known and readily apparent to those of skill in the oligonucleotide synthesis art.
  • the protecting group at the 5'-hydroxy position of the attached nucleosides is removed with acid, preferably trichloroacetic acid.
  • activating reagents that can be used in accordance with this method are well known to those of skill in the art.
  • Preferred activating reagents are tetrazole and activator gold (Beckman Instr. Inc., Palo Alto, CA).
  • the activation step occurs in the presence of the added nucleoside and a trityldiolcyanophosphine compound, which compound replaces the nucleoside phosphoramidite of coventional synthetic methods. Unreacted chains are
  • capping reagents such as acetic anhydride and N-methyl imidazole.
  • the labile trivalent phosphorus linkage is oxidized, preferably with iodine, to the stable, pentavalent phosphodiester linkage of the oligonucleotide.
  • the phosphate protecting groups are removed, the chains are separated from the solid support and the base protecting groups are removed by conventional methods.
  • the compounds of the present invention are useful in treating mammals with hereditary disorders or diseases associated with altered genetic expression mechanisms.
  • diseases are viral infections such as HIV, cytomegalovirus, herpes simplex, hepatitis B, papilloma virus and picornavirus; cancers of the lung, colon, cervix, breast and ovary; inflammatory diseases; and diseases of the immune system such as acquired immunodeficiency syndrome (AIDS), hematological neoplasma and hyperproliferative disorders.
  • viral infections such as HIV, cytomegalovirus, herpes simplex, hepatitis B, papilloma virus and picornavirus
  • cancers of the lung, colon, cervix, breast and ovary cancers of the lung, colon, cervix, breast and ovary
  • inflammatory diseases and diseases of the immune system
  • diseases of the immune system such as acquired immunodeficiency syndrome (AIDS), hematological neoplasma and hyperproliferative disorders.
  • the structures of the compounds of the invention were established by the mode of synthesis, by elemental analysis, and by infrared, nuclear magnetic resonance, and mass spectroscopy. The course of the reactions and identity and homogeneity of the products were assessed by thin layer chromatography or high pressure liquid chromatography.
  • THF stands for tetrahydrofuran
  • DMF stands for N,N-dimethylformamide
  • iPr stands for isopropyl
  • DMT stands for 4, 4'-dimethoxytrityl. Temperatures are given in degrees centigrade.
  • the filtrate was stripped of methanol and a further 1.6 g was collected.
  • the combined solids were triturated in about 100 ml of acetone for three hours and then allowed to sit overnight.
  • the resulting precipitate was filtered and washed with acetone to yield 13.3 g after drying at 40o on a vacuum pump overnight.
  • benzoylchloride was added dropwise over the course of two hours. The reaction was stirred at 15 degrees for a further four hours and decanted from a small amount of insoluble residue into ice water saturated with sodium bicarbonate. The product was extracted into about 2.5 liters of methylene chloride, dried over magnesium sulfate, filtered and
  • Example 3 was added with stirring. After 90 min TLC showed mainly starting material so a further 18 mmol of the sodium salt of the hydroxymethyldioxane was added. The mixture was stirred at 35oC for twelve hours. TLC showed some remaining starting material so a further 8 mmol of sodium salt was added and the reaction stirred for a further four hours at 35o. The reaction was cooled to 10o and dripped into a mixture of ice water and ethyl acetate. The layers were separated and the aqueous layer comprising about 400 ml was extracted three times with 500 ml of ethyl acetate. The ethyl acetate washings were combined, dried over magnesium sulfate, filtered and stripped on the rotovap with a vacuum pump to yield 18.4 g of thick yellow oil that still
  • the 8 g of yellow solid of the previous example was dissolved in 60 ml of dioxane and 60 ml of 0.25 molar sulfuric acid was added. The reaction was stirred at room temperature for two hours and then allowed to stand at room temperature for five days. The pH was adjusted to 7.5 with triethylamine and the reaction stripped at 35o. The reaction was stripped twice with toluene to remove remaining water. The 11 g of residue was dissolved in 150 ml of methylene chloride and chromatographed on 445 ml of silica gel eluting with a gradient from 1 to 10% methanol in dichloromethane.
  • oligomers of examples 8 to 12 were synthesized using standard procedures on an Applied Biosystems model 380B DNA synthesizer with modifications as outlined. In all successful couplings a 5-fold to 10-fold excess of the acyclic monomer from example 7 was used. In the following table. A* indicates a residue of structure:
  • the purity of the oligomers was assessed by reverse phase and ion exchange HPLC.
  • N-(8-bromo-6, 9-dihydro-6-oxo-9-pro ⁇ yl- 3H-purin-2-yl)-2-methylpropamide may be synthesized from N- (8-bromo-6,7-dihydro-6-oxo-3H-purin-2-yl)-2- methylpropanamide of example 15 substituting n-propyl iodide for methyl iodide.
  • compound lla above may be obtained from the bromopurine of example 3 and 2-[(methylamino)methyl]- 1,3-propanediol which is obtained by monomethylation of 2- methylamino-1, 3-propanediol.
  • compound lla above may be obtained from the bromopurine of example 3 and 5-mercaptomethyl-2,2- dimethyl-1, 3-dioxane.
  • 5-mercaptomethyl-2,2- dimethyl-1,3-dioxane may be synthesized from the corresponding alcohol (see example 4) by iodination with
  • oligomers of the invention were tested for nuclease inhibition, for hybridization, and for inhibition of mRNA translation.
  • Antisense oligonucleotides were evaluated (and compared against unmodified oligonucleotides) for their stability in the presence of 10% (v/v) fetal bovine serum (FBS) in RPMI 1640 cell culture media containing 20 mM HEPES buffer (complete media).
  • FBS and human serum are known to contain a 3'—>5' exonuclease activity. This represents the only nuclease activity we have been able to detect in FBS, human serum, and human plasma.
  • Oligonucleotide samples were incubated at 37oC in complete media over a six hour time period and the amount of parent compound determined using an HPLC-based procedure.
  • the compound of example 10 elutes as two major peaks on a GEN-PAK FAX (Waters) anion exchange column.
  • Oligonucleotide concentrations were determined spectrophotometrically utilizing extinction coefficients at 260 nm calculated using the method and values presented by Warsaw, Cantor, and Tinoco [CRC Handbook of Biochemistry and Molecular Biology (G.D. Fasman, editor) 1:589 (1975)].
  • oligonucleotide and its comple- mentary sequence were combined (in 0.1 mM EDTA, 10 mM sodium phosphate, 0.1 M NaCl, pH 7.0) heated to 80oC and allowed to cool slowly at room temperature. Samples were allowed to remain at room temperature for about 2.5 hours. Samples were then heated at a rate of 0.5oC/min (25oC-75oC) in a thermostatically controlled heat block and absorbance monitored at 260 nm using a Perkin Elmer Lambda 4C UV spectrophotometer. A 26O measurements were taken every 15 seconds. Data were transferred to a DEC VAX for data analysis using RS/1 data analysis software. Tm's were determined from a plot of dA260/dT vs. temperature. The Tm is that temperature at which dA260/dT is maximum. The results are presented in Table 2.
  • A* 9-methyl-8-acycloadenosine
  • Example 12 (a diastereomeric mixture) and its complementary strand were annealed overnight at 4oC prior to melting and the rate of temperature increase set at 0.1oC/min over the temperature range of 18oC-38oC with A260 measurements taken every 30 sec.
  • the thermal denaturation profile for this duplex was not very sharp with more than one dA260/dT maximum observed; however, it would indicate that
  • E.coli RNase H Boehringer Mannheim, Indianapolis, IN
  • antisense oligonucleotides was carried out using rabbit reticulocyte lysate (Promega, Madison, WI) in a total volume of 50 uL. 25 uCi of 35S-methionine (New England Nuclear, Boston, MA) was added to each translation reaction. Translations were incubated at 30oC for 10 min., after which time samples were snap frozen on dry ice. Alpha and beta globin chains were separated using SDS- polyacrylamide gel electrophoresis. The 15 cm gels were prepared using electrophoresis buffer (0.1 M sodium
  • gels were stained with coomassie blue, dried and autoradiographed at -70oC for 16 hours.
  • compositions of the present invention include one or more of the compounds of this invention formulated into compositions together with one or more non-toxic physiologically acceptable carriers,
  • adjuvants or vehicles which are collectively referred to herein as carriers, for parenteral injection, for oral administration in solid or liquid form, for rectal or topical administration, and the like.
  • compositions can be administered to humans and animals either orally, rectally, parenterally
  • compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile
  • aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
  • a coating such as lecithin
  • surfactants for example
  • compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents .
  • adjuvants such as preserving, wetting, emulsifying, and dispensing agents .
  • Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • isotonic agents for example sugars, sodium chloride and the like.
  • Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices,
  • liposomes and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone.
  • inert customary excipient such as sodium citrate or dicalcium phosphate
  • fillers or extenders as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid
  • binders as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone.
  • sucrose and acacia sucrose and acacia
  • humectants as for example, glycerol
  • disintegrating agents as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate
  • e solution retarders, as for example, paraffin
  • absorption accelerators as for example, quaternary ammonium compounds
  • wetting agents as for example, cetyl alcohol and glycerol monostearate
  • adsorbents as for example, kaolin and bentonite
  • lubricants as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate or mixtures thereof.
  • the dosage forms may also comprise buffering agents.

Abstract

Compounds of formula (I) wherein R1 is hydrogen, or a blocking group that is compatible with oligonucleotide synthesis; R2 is hydrogen or methyl; R3 is hydrogen or -P(R?4)OR5; R4¿ is chlorine, 4-nitroimidazole, imidazole, tetrazole, triazole or di(lower-alkyl)amino-; R5 is methyl, 2-cyanoethyl or 2,2,2-trichloroethyl; n is from 0 to 2; X is oxygen, sulfur, or -NR6; R6 is hydrogen or lower alkyl; Q is chosen from the group consisting of (a) and (b); R7 is lower-alkyl; and R8 is hydrogen, benzoyl, anisoyl, or lower-alkyl carbonyl and its pharmaceutically acceptable addition salts are nucleotide analogs. Modified oligonucleotides containing the nucleoside analogs of formula (I) are stable to nuclease degradation and are useful in inhibiting gene expression, in sequencing, and in mutagenesis.

Description

ACYCLIC NUCLEOSIDE ANALOGS AND
OLIRONUCLEOTIDE SEOUENCES CONTAINING THEM
Fieid of the Invention
The present invention relates to novel 1,ω- alkylenediol nucleoside analogs, to oligonucleotide
sequences containing these analogs, to processes for preparing the nucleosides and the oligonucleotides
incorporating them, to methods of using the modified oligonucleotides to inhibit nuclease degradation and gene expression, and to compositions containing the modified oligonucleotides.
Information Disclosure Statement
Schneider and Benner [J. Am. Chem. Soc. 11 2 ,
453-455 (1990)] disclose
Figure imgf000003_0001
and oligonucleotide analogs containing this unit. The oligonucleotide analogs were hybridized with complementary natural oligonucleotides. The results were described by the authors as "disappointing for those hoping to use flexible oligonucleotide analogs as antisense compound". The replacement of even a single nucleoside in a nonamer resulted in a melting temperature depression of 12 to 15º in the duplex.
Prisbe et al. [J . Med. Chem . 29, 671-675 (1986)] disclose as antiviral agents:
Figure imgf000004_0001
wherein R is hydrogen or a phosphate residue.
Harnden et al. U.S. Patent 4,965,270 disclose as an antiviral 9-(3-hydroxy-2-hydroxymethylprop-1-oxy)guanine:
Figure imgf000004_0002
Schwartz and his colleages [Science 228, 585-587 (1985); J. Molecular Evolution 29, 284-287 (1989); J.
Molecular Evolution 3-6 (1990)] describe the template directed homooligomerization of acyclic nucleotide analogs. The monomers have the formula
Figure imgf000005_0001
where B is cytosine, thymine, guanine or adenine.
Augustyns, et al Nucleic Acids Research 19 2587-93
(1991) discusses the influence of the incorporation of (S)- 9-(3,4-dihydroxybutyl) adenine on the enzymatic stability and base pairing properties of oligodeoxynucleotides.
Background of the Invention
An antisense compound is a compound that binds to or hybridizes with a nucleotide sequence in a nucleic acid, RNA or DNA, to inhibit the function or synthesis of said nucleic acid. Because of their ability to hybridize with both RNA and DNA, antisense compounds can interfere with gene expression at the level of transcription, RNA
processing or translation.
Antisense molecules can be designed and synthesized to prevent the transcription of specific genes to mRNA by hybridizing with genomic DNA and directly or indirectly inhibiting the action of RNA polymerase. A theoretical advantage of targeting DNA is that only small amounts of antisense compounds may be needed to achieve a therapeutic effect. Alternatively, antisense compounds can be designed and synthesized to hybridize with RNA to inhibit post-transcriptional modification (RNA processing) or protein synthesis (translation) mechanisms or affect mRNA stability. Exemplary target RNAs are messenger RNA (mRNA), transfer RNA (tRNA), ribosomal RNA (rRNA) heterogenous nuclear RNA (hnRNA) and the like. Examples of processing and translation mechanisms include splicing of pre-mRNA to remove introns, capping of the 5' terminus of mRNA, transport to the cytoplasm, hybridization arrest and
Ribonuclease H mediated mRNA hydrolysis.
At the present time, however, the development of practical scientific and therapeutic applications of antisense technologies is hampered by a number of technical problems. Synthetic antisense molecules are susceptible to rapid degradation by nucleases that exist in target cells. The oligonucleotide sequences of antisense DNA or RNA, for example, are destroyed by exonucleases acting at either the 5' or 3' terminus of the nucleic acid. In addition, endonucleases can cleave the DNA or RNA at internal phosphodiester linkages between individual nucleotides. As a result of such cleavage, the effective half-life of
administered antisense compounds is very short,
necessitating the use of large, frequently administered, dosages.
Another problem is the extremely high cost of producing antisense DNA or RNA using available semiautomatic DNA synthesizers.
A further problem relates to the delivery of antisense agents to desired targets within the body and cell. Antisense agents targeted to genomic DNA must gain access to the nucleus (i.e. the agents must permeate the plasma and nuclear membrane). The need for increased membrane perme- ability (increased hydrophobicity) must be balanced, however, against the need for aqueous solubility (increased hydrophilicity in body fluid compartments such as the plasma and cell cytosol.
A still further problem relates to the stability of antisense agents whether free within the body or
hybridized to target nucleic acids. Oligonucleotide
sequences such as antisense DNA are susceptible to steric reconfiguration around chiral phosphorous centers.
Gene targeting via antisense agents is the pre- dieted next step in human therapeutics [Armstrong, Business Week March 5, 1990 p.88]. The successful application of antisense technology to the treatment of disease however, requires finding solutions to the problems set forth above. One approach to preparing antisense compounds that are stable, nuclease resistant, inexpensive to produce and which can be delivered to and hybridize with nucleic acid targets throughout the body is to synthesize oligonucleotide sequences with modifications in the normal phosphate-sugar backbone structure and the point of attachment to the nucleotide base. This invention is directed to such an approach.
Summary of the Invent i on
In a product aspect the invention relates to compounds of formula I
Figure imgf000008_0002
wherein R1 is hydrogen or a blocking group that is
compatible with oligonucleotide synthesis, such as
methoxytrityl, or dimethoxytrityl; R2 is hydrogen, nitro, lower alkyl amino, diloweralkyl amino or methyl; R3 is hydrogen or -P(R4)OR5; R4 is chloro, imidazolyl, 4- nitroimidazolyl, tetrazolyl, triazolyl or dilower-alkylamino preferably diisopropylamino; R5 is methyl, 2,2,2- trichloroethyl or 2-cyanoethyl, preferably 2-cyanoethyl; X is oxygen, sulfur or -NR6-, preferably oxygen; R6 is
hydrogen or lower-alkyl, preferably methyl; n is 0 to 2 and Q is a heterocyclic residue chosen from the group consisting of
Figure imgf000008_0001
wherein R7 is lower-alkyl or loweralkyloxy methylene and R8 is hydrogen, benzoyl, anisoyl or lower-alkylcarbonyl. The point of attachment of the heterocycle O is at the 8- position carbon rather than the 9-position nitrogen as in naturally-occurring nucleosides.
In a further product aspect the invention relates to an oligonucleotide sequence of from about 6 to about 200 bases, preferably from about 12 to about 24 bases, most preferably about 15 bases, in which one or more nucleosides are replaced by a residue of formula V
2
Figure imgf000009_0001
The compounds of formula I are useful as intermediates in the synthesis of the oligonucleotide sequences in which one or more residues are replaced. The
oligonucleotide sequences are useful as antisense agents, for the inhibition of gene expression, in nucleic acid sequencing, diagnostic assays and for the inhibition of nuclease degradation.
For the purposes of the invention lower-alkyl means a hydrocarbon radical consisting of from about one to about four carbons in straight chains, branched or cyclic structures. Nucleoside and nucleotide have their standard meanings in the art: i.e. a nucleoside is a nucleoside base attached to a ribose or a 2-deoxyribose through the 9- position of the purine or the 1-position of the pyrimidine; a nucleotide is a 3' or 5' ribose-O-phosphate ester of a nucleoside. Nucleoside bases comprise uracil, thymine, cytosine, guanine, adenine and their variously modified and derivatized congeners as known in the art. Examples of such modified and derivatized bases include 5-fluorouracil, 5- bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, dihydrouracil, inosine, N6- isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2, 2-dimethylguanine, 2- methyladenine, 2-ethylguanine, 3-methylcytosine, 5-methyl- cytosine, N6-methyladenine, 7-methylguanine, 5-methyl- aminomethyluracil, 5-methoxyuracil, pseudouracil, queuosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4- thiouracil, 5-methyluracil, and 2, 6-diaminopurine. The formulas and substituents retain the definitions initially assigned to them throughout the specification.
In a further composition aspect, the invention relates to compositions for inhibiting gene expression comprising the modified oligonucleotides described above and a pharmaceutically acceptable carrier.
In a method aspect, the invention relates to a method of inhibiting gene expression and to a method of inhibiting nuclease, particularly exonuclease, degradation of oligonucleotide sequences, which comprises providing a modified oligonucleotide described above.
In a process aspect, the invention pertains to processes for preparing compounds of formula II
Figure imgf000010_0001
which comprises reacting a compound of formula III with a compound of formula IV
Figure imgf000010_0002
wherein Y is a leaving group readily displaced by a
nucleophile and R9 and R10 are hydrogen, in which case the compounds of formula II are obtained directly, or protecting groups for a hydroxyl function, in which case the compounds of formula II are obtained by removal of the protecting groups by means known in the art. Preferred leaving groups, Y, are bromine, chlorine, iodine, toluenesulfonate, and methanesulfonate; most preferred is bromine. Preferred protecting groups are t-butyl, benzyl, phenyl or substituted phenyl or isopropylidene; most preferred is isopropylidene.
Compounds of formula III wherein n is 0-2 are commercially available, known in the art or belong to known families of compounds and can be obtained as pure
enantiomers.
In a further process aspect the invention relates to a process for the synthesis of modified oligonucleotides in which a nucleoside is replaced by a residue of formula V
Figure imgf000011_0001
which comprises reacting an oligonucleotide sequence having one free 3' or 5' hydroxyl with a compound of formula VI
D
Figure imgf000011_0002
wherein DMT stands for the dimethoxytrityl residue and Oa is the subset of O wherein R8 is other than hydrogen (R8a) .
Preferably Oa is
-
Figure imgf000011_0003
The oligomers wherein R8 is hydrogen are then obtained from the corresponding R8a oligomers by deprotection using methods well-known in the art.
Detailed Description Inclusive of Preferred Embodiments
Compounds of formula I may be synthesized by the route shown in scheme A:
Figure imgf000013_0001
For guanosine analogs, commercially available 8- bromoguanine is acylated with an appropriate acid chloride or anhydride, preferably isobutyric anhydride, and alkylated with an appropriate lower-alkyl halide or sulfonate, preferably methyl iodide to produce a 2-acyl-9-alkyl-8- bromoguanine of formula Vila. For adenosine analogs, commercially available adenine is alkylated with a lower- alkyl halide or sulfonate, preferably methyl iodide, brominated with molecular bromine at pH 4.0 in aqueous acetic acid-sodium acetate buffer and acylated with an acid chloride or anhydride, preferably benzoyi chloride to produce a 4, 4-diacyl-9-alkyl-8-bromoadenine Vllb.
An 8-bromopurine (eg formulas Vila or Vllb) is reacted with about 2 equivalents of the appropriate
derivative of 1,ω-alkylenediol III in an inert solvent, preferably DMF. In the case where X is oxygen, it is preferred that R9 and R10 together form an isopropylidene residue; i.e. Ill is:
Figure imgf000014_0001
wherein n is 0 to 2, preferably 0 or 1 and it is preferred that the sodium salt of the alcohol be preformed by the addition of one equivalent of sodium hydride. The 8- bromopurine is then added to the alcoholate in the inert solvent. In the case where X is sulfur or -NR6- it is not necessary to protect the 1,ω-dihydroxyl functionality i.e.
R9 and R10 may be hydrogen, and it is not necessary to preform the sulfur or nitrogen anions.
When R9 and R10 are other than hydrogen, it is necessary to convert them to hydrogen after condensation with the bromopurine by appropriate deprotection. Thus in the preferred case where X is oxygen and R9 and R10 together form a propylidene residue (Ilia), deprotection is
accomplished by procedures well known in the art, for example using mild acid such as 0.25M H2SO4 in dioxane. The compounds of formula Ila are prepared for incorporation into oligonucleotide sequences by protection of one hydroxyl with 4, 4' dimethoxytrityl chloride according to procedures well-known in the art [see Schaller, Lerch and Khorana, J. Am. Chem. Soc. 85 3821-3827 (1963)] followed by reaction of the other hydroxyl with about 3 equivalents of 2-cyanoethyl N,N-diisopropylchlorophosphoramidite in THF also according to procedures known in the art [see Sinha et al. Tet. Lett. 24, 5843-5846 (1983)]. The compounds of formula VI that are preferred for further elaboration into sequences are the compounds in which R4 is diisopropylamino and R5 is β-cyanoethyl, but other "monomers" (VI) in which R4 is chlorine, imidazole, 4-nitroimidazole, tetrazole, triazole, or other dilower-alkylamines and R5 is methyl or 2,2,2-trichloroethyl may also be made by procedures known in the art [see Matteucci and Caruthers Tet . Lett. 22., 1859- 1862 (1981) and Schaller et al. op. cit.]
The monomer unit VI and its precursor X are chiral compounds. The racemic mixture that arises from the
synthesis as shown may be incorporated into oligomers, giving rise to diastersomeric sets of oligomers, which may themselves be separated if desired, or the enantiomers may be separated at the monomer stage. Common techniques that may be used if resolution is desired include chromatography on chiral media or the promotion of diasterosomeric esters of X with single enantiomers of chiral acids, separation of the diasteromers and hydrolysis to provide single
enantiomers of X.
The compounds of formula VI are incorporated into oligonucleotide sequences by the substitution of a compound of formula VI for its corresponding dimethoxytrityl
nucleoside phosphoramidite in standard procedures for the synthesis of oligonucleotides. Particularly preferred are solid phase syntheses such as those described by Matteucci and Caruthers [J. Am. Chem. Soc. 103, 3185-3191 (1981)] and Gait [Olignnucieotide Synthesis: A Practical Approach, ed. by M.J. Gait p. 35-81 IRL Press, Washington, D.C. 1984.] The initial step in solid phase synthesis is attachment of a nucleoside to a solid support, preferably a controlled pore glass (CPG) support. The nucleoside is preferably attached to the CPG via a succinate linkage at the 3'-hydroxy position of the nucleoside. Other means of attaching nucleosides to solid supports are known and readily apparent to those of skill in the oligonucleotide synthesis art.
Following attachment of the first nucleoside to the solid support, chain elongation occurs via the
sequential steps of removing the 5'-hydroxy protecting group, activating the 5'-hydroxy group in the presence of a phosphoramidite reagent, adding the desired nucleosides, capping the unreacted nucleosides and oxidizing the
phosphorous linkage. The protecting group at the 5'-hydroxy position of the attached nucleosides is removed with acid, preferably trichloroacetic acid.
Activating reagents that can be used in accordance with this method are well known to those of skill in the art. Preferred activating reagents are tetrazole and activator gold (Beckman Instr. Inc., Palo Alto, CA).
The activation step occurs in the presence of the added nucleoside and a trityldiolcyanophosphine compound, which compound replaces the nucleoside phosphoramidite of coventional synthetic methods. Unreacted chains are
terminated or capped with capping reagents such as acetic anhydride and N-methyl imidazole.
The labile trivalent phosphorus linkage is oxidized, preferably with iodine, to the stable, pentavalent phosphodiester linkage of the oligonucleotide.
After the desired oligonucleotide chain assembly is complete, the phosphate protecting groups are removed, the chains are separated from the solid support and the base protecting groups are removed by conventional methods.
Gaits, supra at 67-70.
The compounds of the present invention are useful in treating mammals with hereditary disorders or diseases associated with altered genetic expression mechanisms. Examples of such diseases are viral infections such as HIV, cytomegalovirus, herpes simplex, hepatitis B, papilloma virus and picornavirus; cancers of the lung, colon, cervix, breast and ovary; inflammatory diseases; and diseases of the immune system such as acquired immunodeficiency syndrome (AIDS), hematological neoplasma and hyperproliferative disorders. Armstrong, supra at 89; Klausner, Biotechnology &, 303 (1990).
Representative embodiments are disclosed in the examples which follow, it will be apparent to those skilled in the art that the examples may be readily modified by standard procedures to produce nucleotide oligomers of other lengths and with other sequences. Targets for synthesis will usually be chosen by substituting a residue of formula Va or Vb for guanosine or adenosine respectively in the
Figure imgf000017_0001
sequence which is to be protected from nuclease degradation or which is complementary to a sequence which is to be disabled.
The structures of the compounds of the invention were established by the mode of synthesis, by elemental analysis, and by infrared, nuclear magnetic resonance, and mass spectroscopy. The course of the reactions and identity and homogeneity of the products were assessed by thin layer chromatography or high pressure liquid chromatography. The abbreviation THF stands for tetrahydrofuran, DMF stands for N,N-dimethylformamide, iPr stands for isopropyl and DMT stands for 4, 4'-dimethoxytrityl. Temperatures are given in degrees centigrade. Example 1
9-Methyladenine
A mixture of 43.2 g (0.23 mol) of adenine and 210 ml of 40% aqueous tetrabutylammonium hydroxide was stirred at room temperature for 30 minutes and 250 ml of methylene chloride was added. To this heterogenous mixture was added 40 ml (0.64 mol) of methyl iodide in 200 ml of methylene chloride. A further 450 ml of methylene chloride was added and the reaction was stirred vigorously for ten hours. The reaction was cooled to 10º and the liquid phase comprising methylene chloride and water was decanted from a milky pre- cipitate which had formed. Methanol was added to the precipitate and the mixture warmed gently to 40º, cooled to 10º and the resulting granular solid filtered off. The solid was recrystallized from 350 ml of water to provide 20.9 g of 9-methyladenine.
Example 2
8-Bromo-9-methyladenine
Fifteen grams (0.1 mol) of 9-methyladenine of Example 1 was dissolved in 1.5 liters of buffer prepared from 30.8 g of sodium acetate, 1.4 liters of water and sufficient acetic acid to provide a pH of 4.0. To this solution was added dropwise 25 ml of bromine in 2 liters of water over a period of two hours. The reaction was stirred a further two hours and the resulting solid filtered off and rinsed with the water. The solid was air dried and warmed to about 50" in about 80 ml of methanol, stripped to a hazy suspension and filtered. The precipitate after rinsing with water and drying at 40º under vacuum overnight weighed 15.6 g. The filtrate was stripped of methanol and a further 1.6 g was collected. The combined solids were triturated in about 100 ml of acetone for three hours and then allowed to sit overnight. The resulting precipitate was filtered and washed with acetone to yield 13.3 g after drying at 40º on a vacuum pump overnight.
Example 3 6-(Dihenzoylamino)-8-bromo-9-methyl-purine
Thirty-four grams (0.15 mol) of 6-amino-8-bromo-9- methylpurine prepared according to the procedure of Example 2 was dissolved in 100 ml of anhydrous pyridine and
stripped. The residue was redissolved in 800 ml of
pyridine, cooled to 0 to 10° and 80 ml (0.69 mol) of
benzoylchloride was added dropwise over the course of two hours. The reaction was stirred at 15 degrees for a further four hours and decanted from a small amount of insoluble residue into ice water saturated with sodium bicarbonate. The product was extracted into about 2.5 liters of methylene chloride, dried over magnesium sulfate, filtered and
stripped. The residue was stripped twice with toluene to remove traces of pyridine, dissolved in about 150 ml of ethyl acetate and seeded. After crystallization had begun a further 70 ml of ethyl acetate was added and after two hours the mixture was chilled and about 34 g of product was collected by filtration. The product was dissolved in about 500 ml of methylene chloride and filtered through about 400 ml of silica gel to yield, after stripping, 21.5 g of 6- (dibenzoylamino)-8-bromo-9-methyl-purine.
Example 4
6-(Benzoylamiro)-9-methyl-B-[5-(2,2,5-trimethyl-1,3-dioxyanyl)methoxy]purine
To a suspension of 1.5 g (37.5 mmol) of 60% sodium hydride in oil was added 5.0 g (31 mmol) of 2,2, 5-trimethyl- 5-[1,3]dioxanemethanol prepared according to the procedure of V.W. Gash, J. Org. Chem. 37, 2197-2201 (1972). The mixture was stirred at 30º for about one hour and 12 g (27 mmol) of 8-bromo-6-(dibenzoylamino)-9-methyl-purine of
Example 3 was added with stirring. After 90 min TLC showed mainly starting material so a further 18 mmol of the sodium salt of the hydroxymethyldioxane was added. The mixture was stirred at 35ºC for twelve hours. TLC showed some remaining starting material so a further 8 mmol of sodium salt was added and the reaction stirred for a further four hours at 35º. The reaction was cooled to 10º and dripped into a mixture of ice water and ethyl acetate. The layers were separated and the aqueous layer comprising about 400 ml was extracted three times with 500 ml of ethyl acetate. The ethyl acetate washings were combined, dried over magnesium sulfate, filtered and stripped on the rotovap with a vacuum pump to yield 18.4 g of thick yellow oil that still
contained mineral oil from the sodium hydride. The 18.4 g of oil was dissolved in 400 ml of methylene chloride containing 1 ml of triethylamine and applied to 250 ml of silica gel. After some impurities had rinsed through, the product was eluted with 10% methanol in dichloromethane containing 0.2% triethylamine. Eight grams of yellow solid product and 1.4 g of a light yellow gum consisting of product and some DMF were obtained.
Example 5
6-Benzoylamino-8-[3-hydroxy-2-(hydroxvmethyl)-2-methylpropoxy]-9-methylpruine
The 8 g of yellow solid of the previous example was dissolved in 60 ml of dioxane and 60 ml of 0.25 molar sulfuric acid was added. The reaction was stirred at room temperature for two hours and then allowed to stand at room temperature for five days. The pH was adjusted to 7.5 with triethylamine and the reaction stripped at 35º. The reaction was stripped twice with toluene to remove remaining water. The 11 g of residue was dissolved in 150 ml of methylene chloride and chromatographed on 445 ml of silica gel eluting with a gradient from 1 to 10% methanol in dichloromethane. The product which came off with 10% methanol in dichloromethane was recrystallized from ethyl acetate to provide 5.25 g of 6-(benzoylamino)-8-[3-hydroxy- 2-(hydroxymethyl)-2-methylproρoxy]-9-methylpurine.
Example 6
Compound X: R2 - methyl, X - oxygen. Qa = Qa1. R7=methyl A solution of 500 mg (13.5 mmol) of the diol from Example 5 in 20 ml of pyridine was stirred with 500 mg (14 mmol) of dimethoxytrityl chloride at room temperature for 18 hours and 1 ml of methanol was added. The reaction was stirred another six hours and poured into saturated aqueous bicarbonate. The product was extracted three times with methylene chloride, washed with water, dried over sodium sulfate, filtered and stripped twice with toluene. The resulting glass was dissolved in 5% methanol in methylene chloride containing about 0.1% triethylamine and
chromatographed on silica gel eluting with a gradient from 1 to 10% methanol in methylene chloride. The product came off at about 2 to 5% methanol in methylene chloride containing about 0.1% triethylamine. The resulting foam was dissolved in a small volume of methanol then two drops of
triethylamine and about 10 ml of water was added and the resulting solid filtered off to yield 530 mg of product.
Example 7
Compound VI: R2 = methyl. R4 - diisopropylamino.
R5 = cyanoethyl. X = oxygen. Qa - Qa 1 and R7 = methyl The condensation of the product of example 6 with phosphoramidite was carried out as described by Sinha et al. Tett. Letters 24, 5843-5846 (1983). The reaction mixture was placed directly on a silica gel column which had been equilibrated with nitrogen-saturated methyl acetate
containing 0.5% triethylamine. Upon elution with the above mixture, 600 mg of product containing a small amount of starting material was obtained. It was rechromatographed on silica gel with nitrogen-saturated 20% ethyl acetate in methylene chloride containing 0.5% triethylamine to obtain 100 mg of pure product.
Examples 8 to 12
The oligomers of examples 8 to 12 were synthesized using standard procedures on an Applied Biosystems model 380B DNA synthesizer with modifications as outlined. In all successful couplings a 5-fold to 10-fold excess of the acyclic monomer from example 7 was used. In the following table. A* indicates a residue of structure:
Figure imgf000022_0001
The purity of the oligomers was assessed by reverse phase and ion exchange HPLC.
Figure imgf000022_0002
Example 13
6-(Benzoylamino)-9-methyl-8-[5-[2,2-dimethyl-1,3-dioxanyl)methoxy]Purine. IX:
R2 =H, R9 + R10 - isopropylidene. X = O, Qa - Qa1 R7 - CH3 By a procedure analogous to that of example 4, 4.17 g of 6-(benzoylamino)-9-methyl-8-[5-(2,2-dimethyl-1, 3- dioxanyl)methoxy]purine was synthesized from 7.4 g (17 mmol) of 8-bromo-6-(dibenzoylamino)-9-methylpurine of example 3 and 5.16 g (35 mmol) of 2,2-dimethyl-5-hydroxymethyl-1, 3- dioxane. Exampl e 14
6-(Benzoyla mino)-8[-3-hydroxy-2-(hydroxymetyl)propoxy]-9-methylpurine IIa
R2=H, X = O, Qa=Qa1 R7=CH3
By a process analogous to that of example 5, 1.5 g of 6-(benzoylamino)-8-[3-hydroxy-2-(hydroxymethyl)propoxy]- 9-methylpurine was synthesized from 4.1 g of the
isopropylidene-protected diol of example 13. The product was recrystallized from methanol/ether; m.p. 151-153º as the monohydrate.
Example 15
N-(8-Broro-6,7-dihydro-6-oxo-3H-purin-2-yl)-2-methylpropanamide, XI; R8a = (CH3)2CHCO-
A suspension of 3.45 g (15 mmol) of 8-bromoguanine in 100 ml of isobutyric anhydride was heated at 150º under nitrogen for 4 hours, cooled and 3.6 g of product filtered off. The product was washed with ether and used in
example 16.
Example 16
N-(8-Bromo-6, 9-dihydro-9-methyl-6-oxo-3H-Purin-2-yl)-2-methylpropanamide.
VIla; R7 =CH3,R8a -(CH3)2CHCO- By a process analogous to that of example 1, 3.0 g
(10 mmol) of N- (8-bromo-6, 7-dihydro-6-oxo-3H-purin-2-yl)-2- methylpropanamide of example 15 was converted to 610 mg of N-(8-bromo-6, 9-dihydro-9-methyl-6-oxo-1H-purin-2-yl) -2- methylpropanamide m.p. 294º (d) from chloroform/hexane.
Example 17
N-(8-bromo-6,9-dihydro-6-oxo-9-propyl-3H-purin.2-yl)-2-methylPropamide.
VIla; R7 -n-prppyl. R8a- (CH3)2CHCO- By a process analogous to that of example 16, it is contemplated that N-(8-bromo-6, 9-dihydro-6-oxo-9-proρyl- 3H-purin-2-yl)-2-methylpropamide may be synthesized from N- (8-bromo-6,7-dihydro-6-oxo-3H-purin-2-yl)-2- methylpropanamide of example 15 substituting n-propyl iodide for methyl iodide. Example 18
compoundIla; R2 =H, X-NCH3, Qa=Qa1R7 - CH3
By a process analogous to that of example 4, it is contemplated that compound lla above may be obtained from the bromopurine of example 3 and 2-[(methylamino)methyl]- 1,3-propanediol which is obtained by monomethylation of 2- methylamino-1, 3-propanediol.
Example 19
Compoundlla; R2=H. X=S.Qa=Qa1R7=CH3
By a process analogous to that of example 4, it is contemplated that compound lla above, may be obtained from the bromopurine of example 3 and 5-mercaptomethyl-2,2- dimethyl-1, 3-dioxane.
It is contemplated that 5-mercaptomethyl-2,2- dimethyl-1,3-dioxane may be synthesized from the corresponding alcohol (see example 4) by iodination with
iodine/triphenyl phosphine followed by displacement with sodium sulfide.
Representative oligomers of the invention were tested for nuclease inhibition, for hybridization, and for inhibition of mRNA translation.
Nurlease Stability
Antisense oligonucleotides were evaluated (and compared against unmodified oligonucleotides) for their stability in the presence of 10% (v/v) fetal bovine serum (FBS) in RPMI 1640 cell culture media containing 20 mM HEPES buffer (complete media). FBS and human serum are known to contain a 3'—>5' exonuclease activity. This represents the only nuclease activity we have been able to detect in FBS, human serum, and human plasma. Oligonucleotide samples were incubated at 37ºC in complete media over a six hour time period and the amount of parent compound determined using an HPLC-based procedure.
The compound of example 10 elutes as two major peaks on a GEN-PAK FAX (Waters) anion exchange column.
These two peaks represent the expected R and S forms of the molecule. After six hours in the presence of 10% FBS, a stable reaction product was observed for example 10. In contrast to the degradation of d(A)15, the progression of the FBS associated 3'—>5' exonuclease activity is halted at the acyclo residue.
Measurement of PNA/DNA Duplex Melting Temperatures
Oligonucleotide concentrations were determined spectrophotometrically utilizing extinction coefficients at 260 nm calculated using the method and values presented by Warsaw, Cantor, and Tinoco [CRC Handbook of Biochemistry and Molecular Biology (G.D. Fasman, editor) 1:589 (1975)].
Equimolar concentrations of oligonucleotide and its comple- mentary sequence were combined (in 0.1 mM EDTA, 10 mM sodium phosphate, 0.1 M NaCl, pH 7.0) heated to 80ºC and allowed to cool slowly at room temperature. Samples were allowed to remain at room temperature for about 2.5 hours. Samples were then heated at a rate of 0.5ºC/min (25ºC-75ºC) in a thermostatically controlled heat block and absorbance monitored at 260 nm using a Perkin Elmer Lambda 4C UV spectrophotometer. A26O measurements were taken every 15 seconds. Data were transferred to a DEC VAX for data analysis using RS/1 data analysis software. Tm's were determined from a plot of dA260/dT vs. temperature. The Tm is that temperature at which dA260/dT is maximum. The results are presented in Table 2.
Figure imgf000026_0001
Total Strand Concentration = 9.0 uM
A* = 9-methyl-8-acycloadenosine Example 12 (a diastereomeric mixture) and its complementary strand were annealed overnight at 4ºC prior to melting and the rate of temperature increase set at 0.1ºC/min over the temperature range of 18ºC-38ºC with A260 measurements taken every 30 sec. The thermal denaturation profile for this duplex was not very sharp with more than one dA260/dT maximum observed; however, it would indicate that
hybridization did occur.
Inhibition of Rabbit Alpha Globin mRNA Translation
Cell free translation of rabbit globin mRNA
(Bethesda Res. Labs, Gaithersburg, MD) +/- 6.5 units/5 uL
E.coli RNase H (Boehringer Mannheim, Indianapolis, IN) with the addition of antisense oligonucleotides was carried out using rabbit reticulocyte lysate (Promega, Madison, WI) in a total volume of 50 uL. 25 uCi of 35S-methionine (New England Nuclear, Boston, MA) was added to each translation reaction. Translations were incubated at 30ºC for 10 min., after which time samples were snap frozen on dry ice. Alpha and beta globin chains were separated using SDS- polyacrylamide gel electrophoresis. The 15 cm gels were prepared using electrophoresis buffer (0.1 M sodium
phosphate, pH 7.2 containing 1.0 g of SDS/L) and contained 12.5% acrylamide and 0.6% bisacrylamide. Aliquots (1 uL) of translation reactions were diluted with 11 uL of loading buffer consisting of electrophoresis buffer, 1.1% 2- mercaptoethanol, 2.5% glycerol and bromphenol blue. Samples were denatured by heating to 100ºC for 3 min. before loading onto gels. The gels were run for 18 hours at 30 mAMP.
After electrophoresis, gels were stained with coomassie blue, dried and autoradiographed at -70ºC for 16 hours.
Quantitation of the effects of alpha globin directed antisense oligonucleotides on the synthesis of alpha globin was done by scanning the autoradiographs using an Ultrascan XL laser densitometer (LKB/Bromma) linked to an AT&T PC6300 computer. Data were collected, displayed and integrated with the Gelscan XL data analysis software package (LKB/Bromma). Effects of oligomers on protein synthesis were expressed as a percent of control alpha globin synthesis. The oligomer of example 8 inhibited translation to 74 ± 10% of control in the absence of RNase H and 84 ± 5% in the presence of RNase H at an oligomer strand concentration of 30 μM.
The pharmaceutical compositions of the present invention include one or more of the compounds of this invention formulated into compositions together with one or more non-toxic physiologically acceptable carriers,
adjuvants or vehicles which are collectively referred to herein as carriers, for parenteral injection, for oral administration in solid or liquid form, for rectal or topical administration, and the like.
The compositions can be administered to humans and animals either orally, rectally, parenterally
(intravenously, intramuscularly or subcutaneously), intracisternally, intravaginally, intraperitioneally, locally (powders, ointments or drops), or as a buccal or nasal spray.
Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile
injectable solutions or dispersions. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (propylene glycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents . Prevention of the action of microorganisms can be ensured by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for example sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for example, aluminum monostearate and gelatin.
If desired, and for more effective distribution, the compounds can be incorporated into slow release or targeted delivery systems such as polymer matrices,
liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (b) binders, as for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone. sucrose and acacia, (c) humectants, as for example, glycerol, (d) disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates and sodium carbonate, (e) solution retarders, as for example, paraffin, (f) absorption accelerators, as for example, quaternary ammonium compounds, (g) wetting agents, as for example, cetyl alcohol and glycerol monostearate, (h) adsorbents, as for example, kaolin and bentonite, and (i) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.

Claims

We claim :
1. A compound of the formula I :
Figure imgf000030_0002
wherein
R1 is hydrogen, or a blocking group that is compatible with oligonucleotide synthesis;
R2 is hydrogen or methyl;
R3 is hydrogen or -P(R4)OR5;
R4 is chlorine, 4-nitroimidazole, imidazole, tetrazole, triazole or di(lower-alkyl)amino-; R5 is methyl, 2-cyanoethyl or 2,2,2- trichloroethyl;
n is from 0 to 2
X is oxygen, sulfur, or -NR6;
R6 is hydrogen or lower alkyl;
Q is chosen from the group consisting of
Figure imgf000030_0001
R7 is lower-alkyl; and
R8 is hydrogen, benzoyi,, anisoyl, or lower-alkyl carbonyl.
2. A compound according to claim 1 wherein R1 and R3 are both hydrogen.
3. A compound according to claim 2 wherein R7 is methyl and n is i.
4. A compound according to claim 3 wherein X is oxygen.
5. A compound of formula
Figure imgf000031_0001
according to claim 4.
6. A compound of formula
Figure imgf000031_0002
according to claim 4.
7. A compound according to claim 1, having the formula;
Figure imgf000031_0003
wherein R8 is benzoyi or lower-alkylcarbonyl.
8. A compound according to claim 7 wherein R5 is cyanoethyl, n is 1 and R4 is diisopropylamino.
9. A compound according to claim 8 wherein X is oxygen.
10. A compound of formula
Figure imgf000032_0001
according to claim 9.
11. A compound comprising an oligonucleotide sequence of from about 6 to about 200 bases in which one or more nucleosides are replaced by a residue of formula
Figure imgf000032_0002
wherein
R2 is hydrogen or methyl;
X is oxygen, sulfur or -NR6;
n is 0 to 2
R6 is hydrogen or lower-alkyl;
Q is chosen from the group consisting of
Figure imgf000033_0001
R7 is lower-alkyl; and
R8 is hydrogen, benzoyi, anisoyl, or lower-alkyl carbonyl.
12. A compound according to claim 11 wherein X is oxygen and n is 1.
13. A compound according to claim 12 wherein said oligonucleotide sequence comprises from about 12 to about 24 bases.
14. A compound according to claim 13 wherein said oligonucleotide sequence comprises 15 bases.
15. A compound of formula
Figure imgf000033_0002
according to claim 14.
16 . A method of inhibit ing nuclease degradat ion of an oligonucleotide comprising replacing one or more nucleosides in said oligonucleotide by a residue of formula
Figure imgf000034_0001
wherein
R2 is hydrogen or methyl;
X is oxygen, sulfur or -NR6;
n is 0 to 2
R6 is hydrogen or lower-alkyl;
Q is chosen from the group consisting of
Figure imgf000034_0002
17. A method of inhibiting gene expression comprising providing an effective amount of a compound according to claim 11.
18. A method of inhibiting gene expression comprising providing an effective amount of a compound according to claim 13.
19. A composition for inhibiting gene expression comprising a compound according to claim 11 and pharmaceutically acceptable carrier.
20. A composition for inhibiting gene expression comprising a compound according to claim 13 and pharmaceutically acceptable carrier.
PCT/US1994/002995 1993-03-30 1994-03-21 Acyclic nucleoside analogs and oligonucleotide sequences containing them WO1994022864A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU64493/94A AU6449394A (en) 1993-03-30 1994-03-21 Acyclic nucleoside analogs and oligonucleotide sequences containing them
DE69404289T DE69404289T2 (en) 1993-03-30 1994-03-21 ACYCLIC NUCLEOSIDE ANALOGS AND THEIR OLIGONUCLEOTIDE SEQUENCES
EP94912266A EP0691968B1 (en) 1993-03-30 1994-03-21 Acyclic nucleoside analogs and oligonucleotide sequences containing them
JP6522133A JPH08508492A (en) 1993-03-30 1994-03-21 Acyclic nucleoside analogues and oligonucleotide sequences containing them
GR970402699T GR3025053T3 (en) 1993-03-30 1997-10-15 Acyclic nucleoside analogs and oligonucleotide sequences containing them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4032693A 1993-03-30 1993-03-30
US08/040,326 1993-03-30

Publications (1)

Publication Number Publication Date
WO1994022864A1 true WO1994022864A1 (en) 1994-10-13

Family

ID=21910387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002995 WO1994022864A1 (en) 1993-03-30 1994-03-21 Acyclic nucleoside analogs and oligonucleotide sequences containing them

Country Status (11)

Country Link
US (1) US5576427A (en)
EP (1) EP0691968B1 (en)
JP (1) JPH08508492A (en)
AT (1) ATE155467T1 (en)
AU (1) AU6449394A (en)
CA (1) CA2159631A1 (en)
DE (1) DE69404289T2 (en)
DK (1) DK0691968T3 (en)
ES (1) ES2107205T3 (en)
GR (1) GR3025053T3 (en)
WO (1) WO1994022864A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739898A2 (en) * 1995-03-13 1996-10-30 Hoechst Aktiengesellschaft Phosphonomonoester nucleic acids, methods for their preparation and their use
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
WO2001034622A1 (en) * 1999-11-08 2001-05-17 Origenix Technologies, Inc. Combinatorial library synthesis and pharmaceutically active compounds produced thereby
WO2002008446A2 (en) * 2000-07-13 2002-01-31 Origenix Technologies, Inc. Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
WO2002100152A2 (en) * 2000-03-27 2002-12-19 Micrologix Biotech, Inc. Solution-phase combinatiorial library synthesis and pharmaceutically active compounds produced thereby
US7256179B2 (en) 2001-05-16 2007-08-14 Migenix, Inc. Nucleic acid-based compounds and methods of use thereof
US20130072421A1 (en) * 2010-05-03 2013-03-21 Curna, Inc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011133876A3 (en) * 2010-04-22 2013-05-16 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs

Families Citing this family (635)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
DE69433036T2 (en) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad AMINODERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US20050118605A9 (en) * 1996-06-06 2005-06-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20040161844A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040171032A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Non-phosphorous-linked oligomeric compounds and their use in gene modulation
US20040161777A1 (en) * 1996-06-06 2004-08-19 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
DE69827060T2 (en) * 1997-03-20 2005-03-24 F. Hoffmann-La Roche Ag Modified primer
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
JP2002515514A (en) 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for local delivery of oligonucleotides
AU745880B2 (en) * 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6335439B1 (en) 1998-06-11 2002-01-01 Isis Pharmaceuticals, Inc. Method of preparing phosphoramidites
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6225293B1 (en) 1998-09-02 2001-05-01 Isis Pharmaceuticals, Inc. Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US6617442B1 (en) * 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
ATE452906T1 (en) * 2000-04-13 2010-01-15 Thomas N Wight THERAPEUTIC SUMMARY AND METHODS FOR MODULATING V3, AN ISOFORM OF VERSICAN
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US6958214B2 (en) 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6548251B1 (en) 2000-09-05 2003-04-15 Fidelity Systems, Inc. Inhibition of molecular and biological processes using modified oligonucleotides
CA2425779C (en) 2000-10-12 2013-08-06 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
JP2004533815A (en) 2001-03-14 2004-11-11 ミリアド・ジェネティックス・インコーポレイテッド TSG101-GAG interaction and use thereof
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
ATE522623T1 (en) 2001-06-20 2011-09-15 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF LUNG TUMORS
EP1404698A4 (en) 2001-06-21 2004-12-22 Isis Pharmaceuticals Inc Antisense modulation of superoxide dismutase 1, soluble expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
EP2153843B1 (en) 2001-09-18 2012-08-15 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
WO2005049075A2 (en) 2003-11-17 2005-06-02 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
JP2005525095A (en) 2002-01-02 2005-08-25 ジェネンテック・インコーポレーテッド Compositions and methods for tumor diagnosis and treatment
US7553619B2 (en) 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US7169916B2 (en) * 2002-04-01 2007-01-30 Isis Pharmaceuticals, Inc. Chloral-free DCA in oligonucleotide synthesis
EP2011886A3 (en) 2002-04-16 2009-02-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7432342B2 (en) 2002-05-03 2008-10-07 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof and related documents
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
EP2116604A1 (en) 2002-08-05 2009-11-11 University of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
EP1537208A1 (en) 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
EP1546170A4 (en) 2002-09-20 2007-08-29 Univ Yale Riboswitches, methods for their use, and compositions for use with riboswitches
US7229976B2 (en) 2002-09-26 2007-06-12 Isis Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
CA2504720C (en) 2002-11-05 2013-12-24 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004041889A2 (en) * 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004044139A2 (en) * 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
AU2003294281B2 (en) 2002-11-13 2010-05-20 Kastle Therapeutics, Llc Antisense modulation of apolipoprotein B expression
SI1569695T1 (en) 2002-11-13 2013-08-30 Genzyme Corporation Antisense modulation of apolipoprotein b expression
CA2506127C (en) 2002-11-15 2013-07-09 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
ES2392511T3 (en) 2002-11-15 2012-12-11 Musc Foundation For Research Development Complement modulators targets on complement receptor 2
EP2410332A1 (en) 2002-11-21 2012-01-25 The University Of Utah Method for identifying purinergic modulators of the olfactory system
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
EP1583843B1 (en) 2002-12-20 2018-07-18 QIAGEN GmbH Single primer whole genome amplification
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6977153B2 (en) * 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7002006B2 (en) * 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
BRPI0410886A (en) 2003-06-03 2006-07-04 Isis Pharmaceuticals Inc double stranded compound, pharmaceutical composition, pharmaceutically acceptable salt, methods of modifying human survivin-encoding nucleic acid, inhibiting suvivin expression in cells or tissues, and treating a condition associated with suvivin expression or overexpression, and single stranded RNA oligonucleotide
DK2336317T3 (en) 2003-06-13 2019-12-16 Alnylam Europe Ag Double-stranded ribonucleic acid with increased efficiency in an organism
US7790691B2 (en) * 2003-06-20 2010-09-07 Isis Pharmaceuticals, Inc. Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
EP1648914A4 (en) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20050053981A1 (en) 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
KR100750788B1 (en) 2003-09-18 2007-08-20 아이시스 파마수티컬즈 인코포레이티드 4 MODULATION OF eIF4E EXPRESSION
EP1677822B1 (en) 2003-09-18 2014-04-23 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP2363480A3 (en) 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US8778900B2 (en) 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en) 2004-03-15 2005-09-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of rna by rnase h
US20050267300A1 (en) 2004-04-05 2005-12-01 Muthiah Manoharan Processes and reagents for oligonucleotide synthesis and purification
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
EP3034510A1 (en) 2004-04-30 2016-06-22 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
JP2008500064A (en) 2004-05-21 2008-01-10 ザ ユーエービー リサーチ ファウンデーション Variable lymphocyte receptor, related polypeptides and nucleic acids, and uses thereof
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2006023880A2 (en) 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
TR201907874T4 (en) 2004-09-23 2019-06-21 Arc Medical Devices Inc Pharmaceutical compositions and methods for inhibiting fibrous adhesions or inflammatory diseases using low sulphate fucans.
WO2006086821A1 (en) 2004-10-20 2006-08-24 Antisense Therapeutics Ltd ANTISENS MODULATION OF INTEGRIN α4 EXPRESSION
WO2006063031A2 (en) * 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
CN101175769A (en) 2005-03-10 2008-05-07 健泰科生物技术公司 Methods and compositions for modulating vascular integrity
EP1863908B1 (en) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transcription and amplification of rna with simultaneous degradation of dna
JP5329949B2 (en) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
MY144014A (en) 2005-08-11 2011-07-29 Synthetic Genomics Inc Method for in vitro recombination
KR20080036646A (en) 2005-08-17 2008-04-28 메덱시스 에스.에이. Composition and method for determination of ck19 expression
DK1931780T3 (en) 2005-08-29 2016-01-25 Regulus Therapeutics Inc Antisense-forbindelser med forøget anti-microrna-aktivitet
CA2620856C (en) 2005-08-29 2017-11-28 Isis Pharmaceuticals, Inc. Methods for use in modulating mir-122a
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
AU2006304321B2 (en) 2005-10-14 2012-10-04 Musc Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
AU2006305886C1 (en) * 2005-10-28 2011-03-17 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
AU2006311730B2 (en) 2005-11-09 2010-12-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Factor V Leiden mutant gene
EP1966377A2 (en) 2005-11-21 2008-09-10 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
JP2009524411A (en) 2005-12-21 2009-07-02 イェール ユニバーシティー Methods and compositions related to the regulation of riboswitches
JP5713377B2 (en) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート Natural antisense and non-coding RNA transcripts as drug targets
PT2161038E (en) 2006-01-26 2014-03-10 Isis Pharmaceuticals Inc Compositions and their uses directed to huntingtin
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
JP5213723B2 (en) 2006-01-27 2013-06-19 アイシス ファーマシューティカルズ, インコーポレーテッド Oligomer compounds and compositions for use in modulating microRNA
KR101304071B1 (en) 2006-01-27 2013-09-06 아이시스 파마수티컬즈 인코포레이티드 6-modified bicyclic nucleic acid analogs
SG170780A1 (en) 2006-03-31 2011-05-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of eg5 gene
AU2007245599B2 (en) 2006-05-03 2012-05-10 Baltic Technology Development, Ltd. Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
EP2505650A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PCSK9
EP2505646A1 (en) * 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
WO2007137156A2 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
WO2007137220A2 (en) 2006-05-22 2007-11-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
US8198253B2 (en) 2006-07-19 2012-06-12 Isis Pharmaceuticals, Inc. Compositions and their uses directed to HBXIP
CA2660052A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of jnk proteins
KR101556798B1 (en) 2006-10-05 2015-10-01 메사츄세츠 인스티튜트 어브 테크놀로지 Multifunctional Encoded Particles for High-Throughput Analysis
EP3916095A1 (en) 2006-10-18 2021-12-01 Ionis Pharmaceuticals, Inc. Antisense compounds
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
EP2453016A1 (en) 2006-11-27 2012-05-16 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
JP2010512327A (en) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Compositions and methods for the treatment of pathological angiogenesis and vascular permeability
EP2913341A1 (en) 2006-12-22 2015-09-02 University of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2121987B1 (en) 2007-02-09 2012-06-13 Northwestern University Particles for detecting intracellular targets
KR20100015757A (en) 2007-03-22 2010-02-12 예일 유니버시티 Methods and compositions related to riboswitches that control alternative splicing
AP2014007971A0 (en) 2007-03-29 2014-09-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
EP2639316A1 (en) 2007-05-11 2013-09-18 The Johns Hopkins University Biomarkers for melanoma
CN101849020A (en) 2007-05-29 2010-09-29 耶鲁大学 The method and composition of riboswitch and use riboswitch
CA2688321A1 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2160464B1 (en) 2007-05-30 2014-05-21 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US7807372B2 (en) * 2007-06-04 2010-10-05 Northwestern University Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
ES2439591T3 (en) 2007-08-15 2014-01-23 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
CA2704729C (en) 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009039466A1 (en) 2007-09-20 2009-03-26 Vanderbilt University Free solution measurement of molecular interactions by backscattering interferometry
WO2009039442A1 (en) 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
EP2222851B1 (en) 2007-11-20 2017-06-28 Ionis Pharmaceuticals, Inc. Modulation of cd40 expression
WO2009076400A2 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
WO2009100320A2 (en) 2008-02-07 2009-08-13 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009111658A2 (en) 2008-03-05 2009-09-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 and vegf genes
EP2282744B1 (en) 2008-03-21 2018-01-17 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
WO2009124238A1 (en) 2008-04-04 2009-10-08 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
US8846639B2 (en) 2008-04-04 2014-09-30 Isis Pharmaceutical, Inc. Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity
CA2720675C (en) 2008-04-18 2019-08-27 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
WO2009134917A2 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
EP2297322A1 (en) 2008-06-04 2011-03-23 The Board of Regents of The University of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
JP2011529686A (en) 2008-07-29 2011-12-15 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Selective inhibition of polyglutamine protein expression
EP2334319B1 (en) 2008-08-25 2017-12-06 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to ctgf
AU2009275387B2 (en) 2008-08-25 2010-07-08 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP2331690B1 (en) 2008-09-02 2016-01-13 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of mutant egfr gene
DK2361256T3 (en) 2008-09-24 2013-07-01 Isis Pharmaceuticals Inc Cyclohexenyl-nucleic acid analogues
DK2356129T3 (en) 2008-09-24 2013-05-13 Isis Pharmaceuticals Inc Substituted alpha-L bicyclic nucleosides
JP5529142B2 (en) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ, インコーポレイテッド Lipid formulation composition and method for inhibiting expression of serum amyloid A gene
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
CN102245186B (en) 2008-10-15 2014-08-27 Isis制药公司 Modulation of factor 11 expression
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
JP5763539B2 (en) 2008-10-24 2015-08-12 アイシス ファーマシューティカルズ, インコーポレーテッド 5 'and 2' bis-substituted nucleosides and oligomeric compounds produced therefrom
KR101692880B1 (en) 2008-11-24 2017-01-04 노오쓰웨스턴 유니버시티 Polyvalent rna-nanoparticle compositions
US20110237649A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
CN102317458B (en) 2008-12-04 2018-01-02 库尔纳公司 Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases
MX358603B (en) 2008-12-04 2018-08-28 Curna Inc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene.
JP5855462B2 (en) 2008-12-10 2016-02-09 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. DsRNA compositions targeting GNAQ and methods for inhibiting expression
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
CA3036963A1 (en) 2009-01-29 2010-08-05 Arbutus Biopharma Corporation Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
WO2010091308A2 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
CN102439149B (en) 2009-02-12 2018-01-02 库尔纳公司 By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF)
PL2396038T3 (en) 2009-02-12 2016-05-31 Curna Inc Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
EP2403946A4 (en) 2009-03-04 2012-11-14 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
NZ594995A (en) 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
US9708604B2 (en) 2009-03-17 2017-07-18 Curna, Inc. Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
EP2419535B1 (en) 2009-04-15 2022-08-17 Northwestern University Delivery of oligonucleotide-functionalized nanoparticles
EP3524275A1 (en) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Innate immune supression enables repeated delivery of long rna molecules
EP2421972A2 (en) 2009-04-24 2012-02-29 The Board of Regents of The University of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2010127195A2 (en) 2009-05-01 2010-11-04 Curna, Inc. Antisense oligonucleotides of hemoglobins
CA3151387A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
WO2010129687A1 (en) 2009-05-05 2010-11-11 Alnylam Pharmaceuticals, Inc Methods of delivering oligonucleotides to immune cells
CN106237345A (en) 2009-05-06 2016-12-21 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
US20120046236A1 (en) 2009-05-06 2012-02-23 Opko Curna Llc Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
EP2430161A1 (en) 2009-05-15 2012-03-21 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
JP5922017B2 (en) 2009-05-18 2016-05-24 クルナ・インコーポレーテッド Treatment of reprogramming factor-related diseases by suppression of natural antisense transcripts against the reprogramming factor
JP2012527248A (en) 2009-05-22 2012-11-08 クルナ・インコーポレーテッド Treatment of TFE3 and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcripts against transcription factor E3 (TFE3)
JP5960049B2 (en) 2009-05-28 2016-08-02 クルナ・インコーポレーテッド Treatment of antiviral gene-related diseases by suppression of natural antisense transcripts against antiviral genes
NZ622843A (en) 2009-06-10 2015-10-30 Tekmira Pharmaceuticals Corp Improved lipid formulation
US20120171170A1 (en) 2009-06-16 2012-07-05 Opko Curna, Llc Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
CN102612560B (en) 2009-06-16 2017-10-17 库尔纳公司 By suppressing to treat the related diseases of PON1 for the natural antisense transcript of PON1 (PON1)
PL3449926T3 (en) 2009-06-17 2020-06-01 Biogen Ma Inc. Compositions and methods for modulation of smn2 splicing in a subject
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
CN102762731B (en) 2009-08-05 2018-06-22 库尔纳公司 By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS)
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US20120157324A1 (en) 2009-08-17 2012-06-21 Yale University Methylation biomarkers and methods of use
EP2470657B1 (en) 2009-08-25 2019-10-23 CuRNA, Inc. Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
ES2599076T3 (en) 2009-09-02 2017-01-31 Genentech, Inc. Smoothened mutant and methods of use thereof
CA2778442A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056687A2 (en) 2009-10-27 2011-05-12 Swift Biosciences, Inc. Polynucleotide primers and probes
AU2010313154B2 (en) 2009-10-30 2016-05-12 Northwestern University Templated nanoconjugates
WO2011053994A1 (en) 2009-11-02 2011-05-05 Alnylam Pharmaceuticals, Inc. Modulation of ldl receptor gene expression with double-stranded rnas targeting the ldl receptor gene promoter
US20130084565A1 (en) 2009-11-03 2013-04-04 University Of Virginia Patent Foundation Versatile, visible method for detecting polymeric analytes
WO2011063403A1 (en) 2009-11-23 2011-05-26 Swift Biosciences, Inc. Devices to extend single stranded target molecules
MX2012006072A (en) 2009-11-30 2012-07-23 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 ).
KR101823702B1 (en) 2009-12-16 2018-01-30 큐알엔에이, 인크. Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
JP6031356B2 (en) 2009-12-23 2016-11-24 カッパーアールエヌエー,インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
DK2516648T3 (en) 2009-12-23 2018-02-12 Curna Inc TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
CN102770540B (en) 2009-12-29 2017-06-23 库尔纳公司 P63 relevant diseases are treated by suppressing the natural antisense transcript of oncoprotein 63 (p63)
EP2519633B1 (en) 2009-12-29 2017-10-25 CuRNA, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
NO2521784T3 (en) 2010-01-04 2018-05-05
US8912157B2 (en) 2010-01-06 2014-12-16 Curna, Inc. Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US8779118B2 (en) 2010-01-11 2014-07-15 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
WO2011088076A2 (en) 2010-01-12 2011-07-21 Yale University Structured rna motifs and compounds and methods for their use
BR112012017483A2 (en) * 2010-01-14 2019-09-24 Haplomics Inc prediction and reduction of alloimmunogenicity of protein therapeutics
KR101853510B1 (en) 2010-01-25 2018-06-20 큐알엔에이, 인크. Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
US9574191B2 (en) 2010-02-03 2017-02-21 The Board Of Regents Of The University Of Texas System Selective inhibition of polyglutamine protein expression
CA2824843A1 (en) 2010-02-04 2011-08-11 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
EP2539452B1 (en) 2010-02-22 2016-07-27 CuRNA, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
BR112012020373A8 (en) 2010-02-23 2018-01-02 Genentech Inc isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tat419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
US9193752B2 (en) 2010-03-17 2015-11-24 Isis Pharmaceuticals, Inc. 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
CA2792291A1 (en) 2010-03-29 2011-10-06 Kumamoto University Sirna therapy for transthyretin (ttr) related ocular amyloidosis
EP3517613A1 (en) 2010-04-09 2019-07-31 CuRNA, Inc. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US20110269194A1 (en) 2010-04-20 2011-11-03 Swift Biosciences, Inc. Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
EP3173419A1 (en) 2010-04-28 2017-05-31 Ionis Pharmaceuticals, Inc. Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
US9127033B2 (en) 2010-04-28 2015-09-08 Isis Pharmaceuticals, Inc. 5′ modified nucleosides and oligomeric compounds prepared therefrom
JP5896175B2 (en) 2010-04-29 2016-03-30 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Regulation of transthyretin expression
CN102958941A (en) 2010-05-03 2013-03-06 霍夫曼-拉罗奇有限公司 Compositions and methods for the diagnosis and treatment of tumor
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
DK2576783T3 (en) 2010-05-26 2018-03-12 Curna Inc TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
CA2801066C (en) 2010-06-02 2021-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
EP2576839B1 (en) 2010-06-07 2017-05-10 Firefly Bioworks, Inc. Nucleic acid detection and quantification by post-hybridization labeling and universal encoding
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
US9638632B2 (en) 2010-06-11 2017-05-02 Vanderbilt University Multiplexed interferometric detection system and method
WO2011163466A1 (en) 2010-06-23 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (nrg-1)
CN103068982B (en) 2010-07-14 2017-06-09 库尔纳公司 DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
ES2756326T3 (en) 2010-07-19 2020-04-27 Ionis Pharmaceuticals Inc Modulation of myotonic dystrophy-protein kinase (DMPK) expression
US20130143955A1 (en) 2010-08-09 2013-06-06 Yale University Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
CA2813901C (en) 2010-10-06 2019-11-12 Curna, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
WO2012054723A2 (en) 2010-10-22 2012-04-26 Opko Curna Llc Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
EP2633052B1 (en) 2010-10-27 2018-04-11 CuRNA, Inc. Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
CN110123830A (en) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare
JP6126009B2 (en) 2010-11-17 2017-05-10 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Regulation of α-synuclein expression
US8987225B2 (en) 2010-11-23 2015-03-24 Curna, Inc. Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012079046A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
US9193973B2 (en) 2010-12-10 2015-11-24 Alynylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (EPO) production
CN103391777A (en) 2011-02-02 2013-11-13 普林斯顿大学理事会 Sirtuin modulators as virus production modulators
TWI593416B (en) 2011-02-02 2017-08-01 艾克厘德製藥公司 Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
EP2670850B1 (en) 2011-02-03 2016-10-26 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
US9222085B2 (en) 2011-02-03 2015-12-29 Mirna Therapeutics, Inc. Synthetic mimics of MIR-124
EP3467109A1 (en) 2011-02-08 2019-04-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9562853B2 (en) 2011-02-22 2017-02-07 Vanderbilt University Nonaqueous backscattering interferometric methods
CA2831284C (en) 2011-03-29 2023-12-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of tmprss6 gene
JP2014511694A (en) 2011-04-03 2014-05-19 ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル Efficient in vivo protein expression using modified RNA (MOD-RNA)
WO2012149154A1 (en) 2011-04-26 2012-11-01 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
US9593330B2 (en) 2011-06-09 2017-03-14 Curna, Inc. Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US9315811B2 (en) 2011-06-10 2016-04-19 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (KLKB1) expression
CN112961855A (en) 2011-06-21 2021-06-15 阿尔尼拉姆医药品有限公司 Angiopoietin-like 3(ANGPTL3) iRNA compositions and methods of use thereof
US9068184B2 (en) 2011-06-21 2015-06-30 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein C (PROC) genes
MX344807B (en) 2011-06-21 2017-01-09 Alnylam Pharmaceuticals Inc Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes.
EP3366312A1 (en) 2011-06-23 2018-08-29 Alnylam Pharmaceuticals, Inc. Serpina 1 sirnas: compositions of matter and methods of treatment
WO2013003808A1 (en) 2011-06-29 2013-01-03 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US20140328811A1 (en) 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
EP3922722B1 (en) 2011-08-11 2023-06-28 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
US9580713B2 (en) 2011-09-17 2017-02-28 Yale University Fluoride-responsive riboswitches, fluoride transporters, and methods of use
MX2014004022A (en) 2011-10-14 2014-04-30 Genentech Inc ANTI-HtrA1 ANTIBODIES AND METHODS OF USE.
US10557136B2 (en) 2011-12-12 2020-02-11 Oncolmmunin Inc. In vivo delivery of oligonucleotides
JP2015501844A (en) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Modified nucleosides, nucleotides and nucleic acid compositions
ES2673960T3 (en) 2011-12-22 2018-06-26 Ionis Pharmaceuticals, Inc. Methods to modulate the expression of a transcript-1 of adenocarcinoma in lung associated with metastases (MALAT-1)
US9556432B2 (en) 2012-01-10 2017-01-31 The Research Foundation For The State University Of New York Method of treating hyperlipidemia and atherosclerosis with miR-30C
US20140378533A1 (en) 2012-02-08 2014-12-25 Isis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
EP2825672B1 (en) 2012-03-13 2019-02-13 Swift Biosciences, Inc. Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
US9340784B2 (en) 2012-03-19 2016-05-17 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
CN104411338A (en) 2012-04-02 2015-03-11 现代治疗公司 Modified polynucleotides for the production of biologics and proteins associated with human disease
DE18200782T1 (en) 2012-04-02 2021-10-21 Modernatx, Inc. MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9914922B2 (en) 2012-04-20 2018-03-13 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US9273949B2 (en) 2012-05-11 2016-03-01 Vanderbilt University Backscattering interferometric methods
US9518261B2 (en) 2012-05-22 2016-12-13 Ionis Pharmaceuticals, Inc. Modulation of enhancer RNA mediated gene expression
WO2014004572A2 (en) 2012-06-25 2014-01-03 Isis Pharmaceuticals, Inc. Modulation of ube3a-ats expression
US20140038182A1 (en) 2012-07-17 2014-02-06 Dna Logix, Inc. Cooperative primers, probes, and applications thereof
EP3693460A1 (en) 2012-07-27 2020-08-12 Ionis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
EP2885312A4 (en) 2012-08-15 2016-01-20 Isis Pharmaceuticals Inc Method of preparing oligomeric compounds using modified capping protocols
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
US9523094B2 (en) 2012-10-11 2016-12-20 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
EP2906699A4 (en) 2012-10-11 2016-06-08 Ionis Pharmaceuticals Inc Oligomeric compounds comprising bicyclic nucleosides and uses thereof
AR092982A1 (en) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc MODULATION OF THE EXPRESSION OF ANDROGEN RECEIVERS
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
HRP20220607T1 (en) 2012-11-26 2022-06-24 Modernatx, Inc. Terminally modified rna
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
JP2016504050A (en) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Signal sensor polynucleotide for modification of cell phenotype
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
DK2951191T3 (en) 2013-01-31 2019-01-14 Ionis Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING OLIGOMERIC COMPOUNDS USING MODIFIED CLUTCH PROTOCOLS
BR112015019515A8 (en) 2013-02-14 2017-10-03 Isis Pharmaceuticals Inc MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
CN105143470B (en) 2013-02-28 2020-06-09 德克萨斯大学系统董事会 Methods for classifying cancer as susceptible to TMEPAI-directed therapy and treating the cancer
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
NZ712336A (en) 2013-03-14 2020-03-27 Alnylam Pharmaceuticals Inc Complement component c5 irna compositions and methods of use thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016522679A (en) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ Therapeutic use of genome editing with the CRISPR / Cas system
US10590412B2 (en) 2013-04-19 2020-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for modulation nucleic acids through nonsense mediated decay
BR112015027321A8 (en) 2013-05-01 2018-01-02 Isis Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES
IL293657A (en) 2013-05-22 2022-08-01 Alnylam Pharmaceuticals Inc Tmprss6 irna compositions and methods of use thereof
PT2999785T (en) 2013-05-22 2018-07-09 Alnylam Pharmaceuticals Inc Serpina1 irna compositions and methods of use thereof
US20160113911A1 (en) 2013-06-06 2016-04-28 The General Hospital Corporation Methods and compositions for the treatment of cancer
DK3007704T3 (en) 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Combination therapy for acromegaly
EP3011026B1 (en) 2013-06-21 2019-12-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
EP3730614A3 (en) 2013-07-02 2020-12-30 Ionis Pharmaceuticals, Inc. Modulators of growth hormone receptor
RS62529B1 (en) 2013-07-11 2021-11-30 Modernatx Inc Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
CA2919268C (en) 2013-07-25 2023-09-05 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
AU2014306271A1 (en) 2013-08-08 2016-03-24 The Scripps Research Institute A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
TW201536329A (en) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
BR112016004093A2 (en) 2013-08-28 2017-10-17 Ionis Pharmaceuticals Inc modulation of pre-kallikrein expression (pkk)
US20160194625A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
HUE045109T2 (en) 2013-09-13 2019-12-30 Ionis Pharmaceuticals Inc Modulators of complement factor b
CN105793423A (en) 2013-10-02 2016-07-20 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting expression of the LECT2 gene
EA201690675A1 (en) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS
SG10201910929QA (en) 2013-10-04 2020-01-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the alas1 gene
EP3055426B1 (en) 2013-10-09 2019-06-19 The United States of America as represented by The Secretary Department of Health and Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
CA2928779A1 (en) 2013-10-21 2015-04-30 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2015061246A1 (en) 2013-10-21 2015-04-30 Isis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
US10301622B2 (en) 2013-11-04 2019-05-28 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA)
CN112107693B (en) 2013-12-03 2023-05-26 西北大学 Liposome particles, method for preparing said liposome particles and use thereof
US10385388B2 (en) 2013-12-06 2019-08-20 Swift Biosciences, Inc. Cleavable competitor polynucleotides
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
JP6710638B2 (en) 2013-12-12 2020-06-17 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Complement component iRNA composition and method of using the same
EP3865144A1 (en) 2013-12-20 2021-08-18 The General Hospital Corporation Methods and assays relating to circulating tumor cells
ES2830257T3 (en) 2013-12-24 2021-06-03 Ionis Pharmaceuticals Inc Modulation of the expression of the angiopoietin-like protein 3
US20170044232A1 (en) 2014-02-04 2017-02-16 Genentech, Inc. Mutant smoothened and methods of using the same
KR20230152154A (en) 2014-02-11 2023-11-02 알닐람 파마슈티칼스 인코포레이티드 KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3119789B1 (en) 2014-03-17 2020-04-22 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
WO2015143245A1 (en) 2014-03-19 2015-09-24 Isis Pharmaceuticals, Inc. Methods for modulating ataxin 2 expression
PL3119888T3 (en) 2014-03-19 2021-12-20 Ionis Pharmaceuticals, Inc. Compositions for modulating ataxin 2 expression
PL3757214T3 (en) 2014-04-01 2022-09-12 Biogen Ma Inc. Compositions for modulating sod-1 expression
HUE056155T2 (en) 2014-04-09 2022-01-28 Scripps Research Inst Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
ES2932304T3 (en) 2014-04-17 2023-01-17 Biogen Ma Inc Compositions and methods for modulation of SMN2 splicing in a subject
US10221416B2 (en) 2014-04-24 2019-03-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
HUE052931T2 (en) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Compositions and methods for modulating angiopoietin-like 3 expression
US10098959B2 (en) 2014-05-01 2018-10-16 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
KR102149571B1 (en) 2014-05-01 2020-08-31 아이오니스 파마수티컬즈, 인코포레이티드 Compositions and methods for modulating growth hormone receptor expression
ES2745825T3 (en) 2014-05-01 2020-03-03 Ionis Pharmaceuticals Inc Compositions and methods for modulating expression of complement factor B
BR112016022855B1 (en) 2014-05-01 2022-08-02 Ionis Pharmaceuticals, Inc COMPOUNDS AND COMPOSITIONS TO MODULATE THE EXPRESSION OF PKK AND ITS USES
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
SG10202104570TA (en) 2014-05-22 2021-06-29 Alnylam Pharmaceuticals Inc Angiotensinogen (agt) irna compositions and methods of use thereof
EP3148564B1 (en) 2014-06-02 2020-01-08 Children's Medical Center Corporation Methods and compositions for immunomodulation
ES2908962T3 (en) 2014-06-10 2022-05-04 Univ Erasmus Med Ct Rotterdam Antisense oligonucleotides useful in the treatment of Pompe disease
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
US9951327B1 (en) 2014-07-17 2018-04-24 Integrated Dna Technologies, Inc. Efficient and rapid method for assembling and cloning double-stranded DNA fragments
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
BR112017001860A2 (en) 2014-07-31 2018-02-27 Uab Research Foundation synthetic peptide, pharmaceutical composition, methods, dosage regimen, and monoclonal antibody
EP3183007B1 (en) 2014-08-19 2020-06-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
CA2959386A1 (en) 2014-08-29 2016-03-03 Lee Adam Wheeler Methods and compositions for the treatment of cancer
US10060921B2 (en) 2014-08-29 2018-08-28 Alnylam Pharmaceuticals, Inc. Methods of treating transthyretin (TTR) mediated amyloidosis
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
KR20170058979A (en) 2014-09-18 2017-05-29 더 유니버시티 오브 브리티쉬 콜롬비아 Allele-specific therapy for huntington disease haplotypes
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
KR20170081257A (en) 2014-11-10 2017-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Combination long acting compositions and methods for hepatitis c
JP2017533252A (en) 2014-11-10 2017-11-09 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Long-acting pharmaceutical composition for hepatitis C
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
WO2016100716A1 (en) 2014-12-18 2016-06-23 Vasant Jadhav Reversirtm compounds
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
US10538763B2 (en) 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
JP2018506715A (en) 2015-01-23 2018-03-08 ヴァンダービルト ユニバーシティー Robust interferometer and method of use
EP3256587A2 (en) 2015-02-13 2017-12-20 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP3262181A4 (en) 2015-02-23 2018-11-21 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
BR112017017178A2 (en) 2015-02-26 2018-04-03 Ionis Pharmaceuticals Inc p23h rhodopsin allele-specific modulators
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
KR20180020125A (en) 2015-03-27 2018-02-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Modified T cells and methods for their manufacture and use
WO2016164746A1 (en) 2015-04-08 2016-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
US10407678B2 (en) 2015-04-16 2019-09-10 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
NZ733882A (en) 2015-04-16 2020-04-24 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
EP3307316A1 (en) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
CA2989970A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
US20180237774A1 (en) 2015-08-04 2018-08-23 Yeda Research And Development Co. Ltd. Methods of screening for riboswitches and attenuators
CN108368507B (en) 2015-09-02 2022-03-22 阿尔尼拉姆医药品有限公司 iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof
WO2017053781A1 (en) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
AU2016334114B2 (en) 2015-10-08 2022-01-27 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
AU2016344399B2 (en) 2015-10-30 2019-03-28 Genentech, Inc. Anti-HtrA1 antibodies and methods of use thereof
WO2017075670A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
BR122023026882A2 (en) 2015-11-06 2024-01-23 Ionis Pharmaceuticals, Inc USE OF AN OLIGOMERIC COMPOUND
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
US10993995B2 (en) 2015-12-07 2021-05-04 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
CA3006599A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
EP3408649B1 (en) 2016-01-29 2023-06-14 Vanderbilt University Free-solution response function interferometry
JP2019509721A (en) 2016-02-04 2019-04-11 キュリス,インコーポレイテッド Mutant smoothened and method of using the same
US10961271B2 (en) 2016-03-16 2021-03-30 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
US10577607B2 (en) 2016-03-16 2020-03-03 Ionis Pharmaceuticals, Inc. Modulation of DYRK1B expression
MA45295A (en) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM
US20190256845A1 (en) 2016-06-10 2019-08-22 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
WO2017219017A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
US20190218257A1 (en) 2016-06-24 2019-07-18 The Scripps Research Institute Novel nucleoside triphosphate transporter and uses thereof
EP3487992A4 (en) 2016-07-21 2020-03-18 Maxcyte, Inc. Methods and compositions for modifying genomic dna
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018055577A1 (en) 2016-09-23 2018-03-29 Synthena Ag Mixed tricyclo-dna, 2'-modified rna oligonucleotide compositions and uses thereof
EP3522898A4 (en) 2016-10-06 2020-05-27 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
JOP20190104A1 (en) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
TW202313978A (en) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 Serpina1 irna compositions and methods of use thereof
EP3548620A4 (en) 2016-12-02 2020-07-22 Cold Spring Harbor Laboratory Modulation of lnc05 expression
TWI790217B (en) 2016-12-16 2023-01-21 美商阿尼拉製藥公司 METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
AU2018210364B2 (en) 2017-01-23 2022-03-17 Regeneron Pharmaceuticals, Inc. HSD17B13 variants and uses thereof
WO2018165564A1 (en) 2017-03-09 2018-09-13 Ionis Pharmaceuticals, Inc. Morpholino modified oligomeric compounds
US20180284123A1 (en) 2017-03-30 2018-10-04 California Institute Of Technology Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
CN110913898A (en) 2017-04-18 2020-03-24 阿尔尼拉姆医药品有限公司 Methods of treating subjects having Hepatitis B Virus (HBV) infection
EP3612546B1 (en) 2017-04-20 2022-07-13 Synthena AG Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018193428A1 (en) 2017-04-20 2018-10-25 Synthena Ag Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
TWI821192B (en) 2017-07-11 2023-11-11 美商新索思股份有限公司 Incorporation of unnatural nucleotides and methods thereof
WO2019014530A1 (en) 2017-07-13 2019-01-17 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
JP2020526558A (en) 2017-07-13 2020-08-31 ノースウェスタン ユニバーシティ Common and direct methods for preparing oligonucleotide functionalized metal-organic framework nanoparticles
KR20200035092A (en) 2017-08-03 2020-04-01 신톡스, 인크. Cytokine conjugates for the treatment of autoimmune diseases
US11197884B2 (en) 2017-08-18 2021-12-14 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. Modulators of smad7 expression
WO2019060442A1 (en) 2017-09-19 2019-03-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
EP3710587A1 (en) 2017-11-16 2020-09-23 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
MX2020006012A (en) 2017-12-18 2020-09-14 Alnylam Pharmaceuticals Inc High mobility group box-1 (hmgb1) irna compositions and methods of use thereof.
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
JP2021511072A (en) 2018-01-15 2021-05-06 アイオニス・ファーマシューティカルズ・インコーポレイテッドIonis Pharmaceuticals,Inc. DNM2 expression modulator
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
CN112004547A (en) 2018-02-26 2020-11-27 新索思股份有限公司 IL-15 conjugates and uses thereof
US11732260B2 (en) 2018-03-02 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-β precursor protein
TW202000199A (en) 2018-03-02 2020-01-01 美商Ionis製藥公司 Modulators of IRF4 expression
WO2019183440A1 (en) 2018-03-22 2019-09-26 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
KR20200141470A (en) 2018-04-06 2020-12-18 칠드런'즈 메디컬 센터 코포레이션 Composition and method for adjusting somatic cell reprogramming and imprinting
SG11202008660TA (en) 2018-04-11 2020-10-29 Ionis Pharmaceuticals Inc Modulators of ezh2 expression
KR20210018267A (en) 2018-05-07 2021-02-17 알닐람 파마슈티칼스 인코포레이티드 Extrahepatic delivery
CN112189053A (en) 2018-05-09 2021-01-05 Ionis制药公司 Compounds and methods for reducing expression of ATXN3
JOP20200280A1 (en) 2018-05-09 2020-11-05 Ionis Pharmaceuticals Inc Compounds and methods for reducing fxi expression
TW202016304A (en) 2018-05-14 2020-05-01 美商阿尼拉製藥公司 Angiotensinogen (agt) irna compositions and methods of use thereof
WO2019241648A1 (en) 2018-06-14 2019-12-19 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing stmn2 expression
JP7315594B2 (en) 2018-06-27 2023-07-26 アイオーニス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for reducing LRRK2 expression
AR115847A1 (en) 2018-07-25 2021-03-03 Ionis Pharmaceuticals Inc COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN2
AU2019321375A1 (en) 2018-08-13 2021-03-11 Alnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof
AR115960A1 (en) 2018-08-16 2021-03-17 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF THE LECT2 GENE
JP2022500442A (en) 2018-09-14 2022-01-04 ノースウェスタン ユニバーシティ Programming of protein polymerization with DNA
CN112424355A (en) 2018-09-18 2021-02-26 阿尔尼拉姆医药品有限公司 Ketohexokinase (KHK) iRNA compositions and methods of use thereof
AU2019350765A1 (en) 2018-09-28 2021-05-27 Alnylam Pharmaceuticals, Inc. Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated ocular diseases
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
CA3119456A1 (en) 2018-11-15 2020-05-22 Ionis Pharmaceuticals, Inc. Modulators of irf5 expression
US20210332495A1 (en) 2018-12-06 2021-10-28 Northwestern University Protein Crystal Engineering Through DNA Hybridization Interactions
CA3123617A1 (en) 2018-12-20 2020-06-25 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
SG11202106489RA (en) 2018-12-20 2021-07-29 Vir Biotechnology Inc Combination hbv therapy
JP2022517270A (en) 2019-01-16 2022-03-07 ジェンザイム・コーポレーション Serpinc1 iRNA composition and its usage
WO2020160453A1 (en) 2019-01-31 2020-08-06 Ionis Pharmaceuticals, Inc. Modulators of yap1 expression
KR20210123299A (en) 2019-02-06 2021-10-13 신톡스, 인크. IL-2 conjugates and methods of use thereof
US11279932B2 (en) 2019-02-27 2022-03-22 Ionis Pharmaceuticals, Inc. Modulators of MALAT1 expression
WO2020205463A1 (en) 2019-03-29 2020-10-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating ube3a-ats
AU2020252710A1 (en) 2019-03-29 2021-11-11 Mitsubishi Tanabe Pharma Corporation Compound, method and pharmaceutical composition for DUX4 expression adjustment
US20220339256A1 (en) 2019-05-13 2022-10-27 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus (hbv) infection
EP3969052A1 (en) 2019-05-17 2022-03-23 Alnylam Pharmaceuticals Inc. Oral delivery of oligonucleotides
BR112021025130A2 (en) 2019-06-14 2022-03-15 Scripps Research Inst Reagents and methods for replication, transcription and translation in semisynthetic organisms
EP3956450A4 (en) 2019-07-26 2022-11-16 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
WO2021022109A1 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4007811A2 (en) 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
EP4013870A1 (en) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Small ribosomal protein subunit 25 (rps25) irna agent compositions and methods of use thereof
EP4013767A4 (en) 2019-08-15 2023-10-25 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds and uses thereof
CN114555128A (en) 2019-08-15 2022-05-27 新索思股份有限公司 Combination immunooncology therapy with IL-2 conjugates
BR112022003046A8 (en) 2019-08-23 2024-02-06 Synthorx Inc Il-15 conjugate, its method of preparation and its uses, as well as pharmaceutical composition and in vitro method of expanding one or more of the t cell populations
BR112022003860A2 (en) 2019-09-03 2022-08-16 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE LECT2 GENE
US20210070827A1 (en) 2019-09-10 2021-03-11 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
EP4045652A1 (en) 2019-10-18 2022-08-24 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
BR112022007540A2 (en) 2019-10-22 2022-07-12 Alnylam Pharmaceuticals Inc COMPONENTS COMPLEMENTARY C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021087325A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023500661A (en) 2019-11-01 2023-01-10 アルナイラム ファーマシューティカルズ, インコーポレイテッド HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
MX2022005251A (en) 2019-11-04 2022-06-08 Synthorx Inc Interleukin 10 conjugates and uses thereof.
MX2022005220A (en) 2019-11-06 2022-08-11 Alnylam Pharmaceuticals Inc Extrahepatic delivery.
EP4055165A1 (en) 2019-11-06 2022-09-14 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
WO2021102373A1 (en) 2019-11-22 2021-05-27 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
TW202140509A (en) 2019-12-13 2021-11-01 美商阿尼拉製藥公司 Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
WO2021126734A1 (en) 2019-12-16 2021-06-24 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
TW202140786A (en) 2020-02-10 2021-11-01 美商艾爾妮蘭製藥公司 Compositions and methods for silencing vegf-a expression
MX2022010052A (en) 2020-02-18 2022-09-05 Alnylam Pharmaceuticals Inc Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof.
MX2022010602A (en) 2020-02-28 2022-09-09 Ionis Pharmaceuticals Inc Compounds and methods for modulating smn2.
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
WO2021178736A1 (en) 2020-03-06 2021-09-10 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4121534A1 (en) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en) 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
JP2023520582A (en) 2020-04-06 2023-05-17 アルナイラム ファーマシューティカルズ, インコーポレイテッド Compositions and methods for silencing MYOC expression
WO2021206922A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
WO2021207189A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing scn9a expression
EP4133076A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
BR112022021813A2 (en) 2020-04-27 2023-01-17 Alnylam Pharmaceuticals Inc APOLIPOPROTEIN AND (APOE) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
JP2023523790A (en) 2020-04-30 2023-06-07 アルナイラム ファーマシューティカルズ, インコーポレイテッド COMPLEMENT FACTOR B (CFB) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA3181546A1 (en) 2020-05-01 2021-11-04 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating atxn1
WO2021230286A1 (en) 2020-05-12 2021-11-18 田辺三菱製薬株式会社 Compound, method and pharmaceutical composition for regulating expression of ataxin 3
WO2021231691A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150076A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231698A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4150090A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150088A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021237097A1 (en) 2020-05-21 2021-11-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
AR122534A1 (en) 2020-06-03 2022-09-21 Triplet Therapeutics Inc METHODS FOR THE TREATMENT OF NUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH MSH3 ACTIVITY
JP2023530234A (en) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド Compositions and methods for treating neoplasms
WO2021252557A1 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
CA3184289A1 (en) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
BR112022026316A2 (en) 2020-06-24 2023-03-07 Vir Biotechnology Inc ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND THEIR USES
KR20230027235A (en) 2020-06-25 2023-02-27 신톡스, 인크. Immuno-oncology combination therapy using IL-2 conjugates and anti-EGFR antibodies
MX2022016338A (en) 2020-06-29 2023-01-24 Ionis Pharmaceuticals Inc Compounds and methods for modulating plp1.
US20230257745A1 (en) 2020-07-10 2023-08-17 Alnylam Pharmaceuticals, Inc. Circular siRNAs
WO2022066847A1 (en) 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
EP4225917A1 (en) 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP3978608A1 (en) 2020-10-05 2022-04-06 SQY Therapeutics Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
AU2021356610A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
JP2023546009A (en) 2020-10-09 2023-11-01 シンソークス, インコーポレイテッド Immuno-oncology combination therapy with IL-2 conjugate and pembrolizumab
WO2022087041A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (en) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
TW202237841A (en) 2020-11-13 2022-10-01 美商艾拉倫製藥股份有限公司 Coagulation factor v (f5) irna compositions and methods of use thereof
EP4136092A4 (en) 2020-11-18 2023-10-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
TW202237150A (en) 2020-12-01 2022-10-01 美商艾拉倫製藥股份有限公司 Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
WO2022125490A1 (en) 2020-12-08 2022-06-16 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
WO2022140702A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
WO2022147223A2 (en) 2020-12-31 2022-07-07 Alnylam Pharmaceuticals, Inc. 2'-modified nucleoside based oligonucleotide prodrugs
KR20230136130A (en) 2020-12-31 2023-09-26 알닐람 파마슈티칼스 인코포레이티드 Cyclic-disulfide modified phosphate-based oligonucleotide prodrug
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
JP2024508714A (en) 2021-02-12 2024-02-28 アルナイラム ファーマシューティカルズ, インコーポレイテッド Superoxide dismutase 1 (SOD1) iRNA composition and method for using the same for treating or preventing superoxide dismutase 1- (SOD1-) related neurodegenerative diseases
TW202245843A (en) 2021-02-12 2022-12-01 美商欣爍克斯公司 Skin cancer combination therapy with il-2 conjugates and cemiplimab
CN117222739A (en) 2021-02-25 2023-12-12 阿尔尼拉姆医药品有限公司 Prion protein (PRNP) IRNA compositions and methods of use thereof
TW202302847A (en) 2021-02-26 2023-01-16 美商艾拉倫製藥股份有限公司 Ketohexokinase (khk) irna compositions and methods of use thereof
IL305414A (en) 2021-03-04 2023-10-01 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
EP4304640A1 (en) 2021-03-12 2024-01-17 Northwestern University Antiviral vaccines using spherical nucleic acids
WO2022212231A2 (en) 2021-03-29 2022-10-06 Alnylam Pharmaceuticals, Inc. Huntingtin (htt) irna agent compositions and methods of use thereof
AU2022249318A1 (en) 2021-03-31 2023-10-12 Entrada Therapeutics, Inc. Cyclic cell penetrating peptides
WO2022212153A1 (en) 2021-04-01 2022-10-06 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
WO2022231999A1 (en) 2021-04-26 2022-11-03 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
EP4330396A1 (en) 2021-04-29 2024-03-06 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
EP4334448A1 (en) 2021-05-03 2024-03-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
WO2022241408A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Compositions and methods for modulating tissue distribution of intracellular therapeutics
EP4337263A1 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
EP4337261A2 (en) 2021-05-10 2024-03-20 Entrada Therapeutics, Inc. Compositions and methods for modulating mrna splicing
WO2022245583A1 (en) 2021-05-18 2022-11-24 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
WO2022246023A1 (en) 2021-05-20 2022-11-24 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
TW202317762A (en) 2021-06-02 2023-05-01 美商艾拉倫製藥股份有限公司 Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2022256534A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2022256290A2 (en) 2021-06-04 2022-12-08 Alnylam Pharmaceuticals, Inc. HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
WO2022260939A2 (en) 2021-06-08 2022-12-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
AU2022293556A1 (en) 2021-06-18 2024-01-18 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing ifnar1 expression
AU2022298774A1 (en) 2021-06-23 2023-12-14 Entrada Therapeutics, Inc. Antisense compounds and methods for targeting cug repeats
WO2023278410A1 (en) 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
TW202333748A (en) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
WO2023003922A1 (en) 2021-07-21 2023-01-26 Alnylam Pharmaceuticals, Inc. Metabolic disorder-associated target gene irna compositions and methods of use thereof
TW202325312A (en) 2021-07-23 2023-07-01 美商艾拉倫製藥股份有限公司 Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en) 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
IL310244A (en) 2021-08-03 2024-03-01 Alnylam Pharmaceuticals Inc Transthyretin (ttr) irna compositions and methods of use thereof
IL310295A (en) 2021-08-04 2024-03-01 Alnylam Pharmaceuticals Inc iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
IL310407A (en) 2021-08-13 2024-03-01 Alnylam Pharmaceuticals Inc Factor xii (f12) irna compositions and methods of use thereof
CA3229661A1 (en) 2021-09-01 2023-03-09 Xiang Li Compounds and methods for skipping exon 44 in duchenne muscular dystrophy
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023044094A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
WO2023064530A1 (en) 2021-10-15 2023-04-20 Alnylam Pharmaceuticals, Inc. Extra-hepatic delivery irna compositions and methods of use thereof
WO2023069603A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023076450A2 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202333749A (en) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 Complement factor b (cfb) irna compositions and methods of use thereof
WO2023092060A1 (en) 2021-11-18 2023-05-25 Cornell University Microrna-dependent mrna switches for tissue-specific mrna-based therapies
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023220744A2 (en) 2022-05-13 2023-11-16 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides
WO2024006999A2 (en) 2022-06-30 2024-01-04 Alnylam Pharmaceuticals, Inc. Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175325A2 (en) * 1984-09-20 1986-03-26 Pierrel S.p.A. New 8-substituted nucleoside and purine derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them
EP0313289A2 (en) * 1987-10-22 1989-04-26 Beecham Group Plc Process for the preparation of purine compounds and intermediates therefor
EP0353955A2 (en) * 1988-08-02 1990-02-07 Beecham Group Plc Novel compounds
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
EP0413544A2 (en) * 1989-08-17 1991-02-20 Beecham Group p.l.c. Purine derivatives, process for their preparation, pharmaceutical compositions and intermediates
EP0520552A1 (en) * 1991-06-21 1992-12-30 PIERREL S.p.A. Derivatives of (hetero) aromatic ethers and thioethers having antihyperlipidemic activity, process for their preparation and pharmaceutical compositions containing them

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0175325A2 (en) * 1984-09-20 1986-03-26 Pierrel S.p.A. New 8-substituted nucleoside and purine derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them
US4965270A (en) * 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
EP0313289A2 (en) * 1987-10-22 1989-04-26 Beecham Group Plc Process for the preparation of purine compounds and intermediates therefor
EP0353955A2 (en) * 1988-08-02 1990-02-07 Beecham Group Plc Novel compounds
EP0413544A2 (en) * 1989-08-17 1991-02-20 Beecham Group p.l.c. Purine derivatives, process for their preparation, pharmaceutical compositions and intermediates
EP0520552A1 (en) * 1991-06-21 1992-12-30 PIERREL S.p.A. Derivatives of (hetero) aromatic ethers and thioethers having antihyperlipidemic activity, process for their preparation and pharmaceutical compositions containing them

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0739898A2 (en) * 1995-03-13 1996-10-30 Hoechst Aktiengesellschaft Phosphonomonoester nucleic acids, methods for their preparation and their use
EP0739898A3 (en) * 1995-03-13 1998-09-16 Hoechst Aktiengesellschaft Phosphonomonoester nucleic acids, methods for their preparation and their use
US5874553A (en) * 1995-03-13 1999-02-23 Hoechst Aktiengesellschaft Phosphonomonoester nucleic acids, process for their preparation, and their use
US6127346A (en) * 1995-03-13 2000-10-03 Hoechst Aktiengesellschaft Phosphonomonoester nucleic acids process for their preparation and their use
WO1998039344A1 (en) * 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
US7285543B2 (en) 1997-03-07 2007-10-23 Metabasis Therapeutics, Inc. Purine inhibitors of fructose-1,6-bisphosphatase
US6967193B1 (en) 1997-03-07 2005-11-22 Metabasis Therapeutics, Inc. Purine inhibitors of fructose-1,6-bisphosphatase
US6620796B1 (en) 1999-11-08 2003-09-16 Micrologix Biotech Inc. Combinatorial library synthesis and pharmaceutically active compounds produced thereby
WO2001034622A1 (en) * 1999-11-08 2001-05-17 Origenix Technologies, Inc. Combinatorial library synthesis and pharmaceutically active compounds produced thereby
WO2002100152A2 (en) * 2000-03-27 2002-12-19 Micrologix Biotech, Inc. Solution-phase combinatiorial library synthesis and pharmaceutically active compounds produced thereby
WO2002100152A3 (en) * 2000-03-27 2003-04-03 Origenix Technologies Inc Solution-phase combinatiorial library synthesis and pharmaceutically active compounds produced thereby
WO2002008446A3 (en) * 2000-07-13 2002-08-15 Origenix Technologies Inc Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
WO2002008446A2 (en) * 2000-07-13 2002-01-31 Origenix Technologies, Inc. Synthesis and antiviral evaluation of nucleic acid based (nab) libraries
US7256179B2 (en) 2001-05-16 2007-08-14 Migenix, Inc. Nucleic acid-based compounds and methods of use thereof
US7709449B2 (en) 2001-05-16 2010-05-04 Migenix, Inc. Nucleic acid-based compounds and methods of use thereof
WO2011133876A3 (en) * 2010-04-22 2013-05-16 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US20130072421A1 (en) * 2010-05-03 2013-03-21 Curna, Inc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US9089588B2 (en) * 2010-05-03 2015-07-28 Curna, Inc. Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT)
US11408004B2 (en) 2010-05-03 2022-08-09 Curna, Inc. Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a Sirtuin (SIRT)

Also Published As

Publication number Publication date
AU6449394A (en) 1994-10-24
EP0691968B1 (en) 1997-07-16
US5576427A (en) 1996-11-19
EP0691968A1 (en) 1996-01-17
DE69404289T2 (en) 1998-02-19
ATE155467T1 (en) 1997-08-15
ES2107205T3 (en) 1997-11-16
CA2159631A1 (en) 1994-10-13
DK0691968T3 (en) 1998-02-23
JPH08508492A (en) 1996-09-10
GR3025053T3 (en) 1998-01-30
DE69404289D1 (en) 1997-08-21

Similar Documents

Publication Publication Date Title
EP0691968B1 (en) Acyclic nucleoside analogs and oligonucleotide sequences containing them
EP0691980B1 (en) 7-deazapurine modified oligonucleotides
US7569686B1 (en) Compounds and methods for synthesis of bicyclic nucleic acid analogs
US5596091A (en) Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
CN106795197B (en) Modified oligonucleotide and preparation method thereof
EP0506242B1 (en) Method and compounds for solid phase synthesis of oligonucleotides and oligonucleotide analogs
US5750692A (en) Synthesis of 3-deazapurines
US5457191A (en) 3-deazapurines
US5948903A (en) Synthesis of 3-deazapurines
EP0339842A2 (en) Novel oligoribonucleotide derivatives and application thereof to antiviral agents
JP2000095793A (en) 2'-o-alkylated guanosine 3'-phosphoroamidite
EP0316017B1 (en) 2',3'-Dideoxy-2'-fluoronucleosides
WO1997030064A1 (en) Hexitol containing oligonucleotides and their use in antisense strategies
WO1995018139A1 (en) Synthesis of propargyl modified nucleosides and phosphoramidites and their incorporation into defined sequence oligonucleotides
JP3675847B2 (en) Method for synthesizing nucleotide or oligonucleotide phosphoramidites
JP3119871B2 (en) Oligodeoxyribonucleotides
US20040033967A1 (en) Alkylated hexitol nucleoside analogues and oligomers thereof
EP0739902B1 (en) H-Phosphonate ribonucleotide derivatives
NZ292140A (en) Oligomers consisting of 1,5-anhydrohexitol nucleosides, antisence techniques.
RU2401272C2 (en) Oligonucleotide purification
US6017895A (en) Oligonucleotides possessing zwitterionic moieties
US6103891A (en) Method for the synthesis of nucleotide or oligonucleotide phosphoramidites
WO1993010140A1 (en) Oligonucleotides having modified anionic moieties
EP0641354A1 (en) Oligonucleotides having aminohydrocarbon phosphonate moieties

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CZ FI HU JP KR NO NZ RU SK UA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994912266

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994912266

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1994912266

Country of ref document: EP